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Summary 
Drug resistant microbes have become widely prevalent and are a large clinical 
burden. Infectious diseases have again become life threatening and affect 
millions of people each year because of the rapid evolution of drug resistance. 
Therefore, the development of antibiotics with novel antimicrobial mechanisms 
of action is highly prioritized. AMPs are antimicrobials with potential to fulfill 
this need because of their differences from traditional antibiotics.  
Ib-AMP4 has been isolated from Impatiens balsamina and exhibits broad 
antimicrobial activity against plant pathogens. Large amounts of Ib-AMP4 were 
prepared by expressing the peptide in Escherichia coli. Bacteria showing 
resistance to current antibiotics are susceptible to AMPs. No cross-resistance 
was observed between present antibiotics and AMPs. Ib-AMP4 has shown 
promising antimicrobial effects against human pathogens, including the most 
prevalent MDR species of MRSA and ESBL-producing E. coli. When 
combined with other antimicrobials, Ib-AMP4 restored the susceptibility of 
MDR strains and greatly reduced the amount of antimicrobial agents required 
for efficacy. However, the antimicrobial efficiency of Ib-AMP4 was also largely 
affected by cations, especially divalent cations. 
To determine the mechanism of action underlying the antimicrobial activity of 
Ib-AMP4, LPS from bacterial cell walls and lipids from biomembranes were 
used to construct an in vitro model system. We found that in the presence of 
Ca2+, our model system of the LPS-Re monolayer absorbed Ca2+ and became 
increasingly compact. Bacterial pathogens used Ca2+ 
The cytoplasmic membrane is the primary target of Ib-AMP4’s rapid 
bactericidal effect. Liposome leakage assays and QCM-D indicate that 
Ib-AMP4 may intercalate into the DOPC bilayer membrane, thereby resulting 
in liposomal leakiness, surface swelling, and wrinkling. The development of 
pores develop within the lipid bilayer is still unknown. However, pore 
development most likely follows the “sinking raft” model because the Ib-AMP4 
structure includes a large hydrophilic headgroup coupled to a short and small 
hydrophobic tail. After the initial insertion of Ib-AMP4, a rapid and intensive 
leakage occurred for approximately 20 min. Along with this leakage, the 
insertion of Ib-AMP4 continued in a “self-promoting” pattern, in which the initial 
insertion of Ib-AMP4 induced further insertions of Ib-AMP4. Surface pressure, 
line tension, and curvature strain were likely involved in the formation and 
resealing of the pores. Studies using single DOPC and DOPC/DOPG binary 
monolayers in calcium-loaded and -free buffers indicated that the charge 
properties of the lipids and cations in the buffer affect the insertion of Ib-AMP4 
regardless of surface pressure. Cholesterol may inhibit calcein leakage caused 
by Ib-AMP4 by changing the membrane’s compressibility and curvature. 
Cations may also inhibit Ib-AMP4 insertion into membranes either by 
interrupting the conformational change of Ib-AMP4 during the insertion stage 
or by electrically repelling Ib-AMP4. Such inhibition is similar to that with cell 
wall LPS.   
to repel Ib-AMP4 
electrically, thereby reducing cell wall permeability to Ib-AMP4.   
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Zusammenfassung 
Medikamtentenresistente Mikroorganismen sind heutzutage weit verbreitet 
und stellen ein bedeutsames klinisches Problem dar.  Dabei ist es der 
rapiden Evolution von Resistenzen geschuldet, dass Infektionskrankheiten 
mittlerweile wieder lebensbedrohliche Ausmaße annehmen können. 
Folgerichtig kommt der Entwicklung von Antibiotika mit neuartigen 
Wirkmechanismen oberste Priorität zu. AMPs sind antimikrobielle Substanzen, 
die sich von herkömmlichen Antibiotika  unterscheiden und über das Potential 
verfügen dieser Anforderung gerecht zu werden. 
Ib-AMP4 wurde aus Impatiens balsamina isoliert und zeigte breite 
antimikrobielle Aktivität gegenüber Pflanzenpathogenen. Große Mengen von 
Ib-AMP4 wurden durch die Expression des Peptids in Escherichia coli 
hergestellt. Auch Bakterien, welche gegen gegenwärtige Antibiotika resistent 
sind, sind für Ib-AMP4 empfänglich. Es wurden keinerlei Kreuzresistenzen 
zwischen Ib-AMP4 und sich im Umlauf befindlichen Antibiotika festgestellt. 
Ib-AMP4 offenbarte vielversprechende Effekte gegen humane 
Krankheitserreger, wie zum Beispiel die am weitesten verbreiteten 
MDR-Stämme von MRSA und ESBL-produzierende E. coli. In Kombination mit 
anderen antimikrobiellen Stoffen, stellte Ib-AMP4 die Empfindlichkeit von 
MDR-Stämmen wiederher und reduzierte die Menge der benötigten 
antimikrobiellen Substanzen erheblich. Jedoch vermochten es Kationen – 
insbesondere divalente Kationen – die antimikrobielle Wirksamkeit zu 
beeinflussen. 
Um den der antimikrobiellen Aktivität zu Grunde liegenden Mechanismus des 
Ib-AMP4 aufzuklären, wurden LPS aus bakteriellen Zellwänden und Lipide aus 
Biomembranen dazu benutzt, um ein in vitro Modell zu entwerfen. Daraus 
wurde ersichtlich, dass das Modellsystem aus LPS-Re in Gegenwart von 
Ca2+ selbiges absorbierte und kompakter wurde. Bakterielle Pathogene 
benutzten Ca2+
Die Zellmembran ist der Hauptangriffspunkt des bakterizid wirkenden Ib-AMP4. 
Die gestörte Liposomenintegrität  in „Liposome leakage assays“ und QCM-D 
deutet darauf hin, dass Ib-AMP4 in die DOPC-Doppelschicht interkaliert und 
dadurch Lecks in den Liposomen, das Anschwellen der Oberfläche und 
Runzelbildung induziert. Die Entstehung von Poren innerhalb der 
Lipiddoppelschicht ist noch immer ungeklärt. Am wahrscheinlichsten ist 
allerdings die Bildung entsprechend dem „sinking raft“ Modell, da Ib-AMP4 
eine große hydrophile Kopfgruppe besitzt, welche an einen kurzen 
hydrophoben Schwanz gekoppelt ist. Nach der anfänglichen Insertion des 
Ib-AMP4 kam es zu raschen und intensiven, ungefähr 20 Minuten 
andauernden Leckverlusten. Zusammen mit diesen Leckverlusten, waren 
weitere, sich selbst fortpflanzende Insertionen von Ib-AMP4 zu beobachten, 
die durch den initialen Einbau von Ib-AMP4 vermittelt wurden. 
Oberflächenspannung, Linienspannung und Krümmungspannung trugen wohl 
zur Entstehung und Versiegelung der Poren bei. Untersuchungen, die binäre 
DOPC und DOPC/DOPG Einzelschichten in calciumhaltigem und 
calciumfreiem Puffer lassen vermuten, dass die Ladung der Lipide und 
Kationen im Puffer die Insertion von Ib-AMP4 unabhängig von der 
Oberflächenspannung beeinflusst. Cholesterin könnte die Calceinfreisetzung 
durch Ib-AMP4  unterbinden, indem es die Membrankompressibilität und die 
Krümmung verändert. Kationen könnten die Insertion von Ib-AMP4 in 
Membranen ebenfalls inhibieren, indem sie entweder dessen 
Konformationsänderung während der Insertionsphase unterbrechen oder 
Ib-AMP4 elektrisch abstoßen. Diese Art der Inhibierung ähnelt jener durch 
Zellwand-LPS. 
, um Ib-AMP4 elektrisch abzustoßen und somit dessen 
Zellwandpermeabilität herabzusetzen. 
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Chapter 1. General introduction 
 1.1 Global infectious diseases and drug resistant bacteria 
A study performed in 2009 reported that more than 15% of clinical Escherichia 
coli isolates in Europe were resistant to third generation cephalosporins (WHO 
2011). Furthermore, MRSA infections have been occurring in Latin America, 
and more than 26% of clinical isolates have been drug resistant (WHO 2007). 
According to a recent release from the World Health Organization (WHO), 
Escherichia coli and Klebsiella pneumoniae resistant to cephalosporins and 
Staphylococcus aureus resistant to methicillin have exceeded 50% of isolates 
found in multiple sites nationally as shown in Table1 (WHO 2014). Bacterial 
resistance to third generation cephalosporins means that infections with these 
bacteria can only be treated using carbapenems, which are generally 
considered a last resort when treating severe infections. Notably, in some 
regions, the proportion of Klebsiella pneumoniae resistant to carbapenems has 
reached over 50% of isolates (Table 1). Community acquired bacteria, such as 
Streptococcus pneumoniae, nontyphoidal Salmonella, Shigella species and 
Neisseria gonorrhoeae, have also displayed a rapid increase in antimicrobial 
resistance. Overall, resistance has increased the burden on and doubled the 
mortality in clinical practices (Table 2). Presently, approximately 60,000 people 
in Europe and the United States die each year due to serious infections 
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caused by antimicrobial resistant bacterial pathogens, primarily those acquired 
in health-care settings (WHO 2014). 
Table 1 Bacteria commonly causing infections in hospitals and communities (WHO, 2014) 
Name of bacterium/ 
resistance 
 
Examples of typical 
diseases 
 
No. of 194 states 
providing 
national data 
 
No. of WHO regions with 
national reports of 50 % 
resistance or more 
 
Range of reported 
proportion of 
resistance 
 
Escherichia coli 
 
Urinary tract infections, 
blood stream infections 
 
   
-vs 3rd gen. cephalosporins 
 
84 5/6 
-vs fluoroquinolones 
0-82 
 
90 5/6 
Klebsiella pneumoniae 
3-96 
 
Pneumonia, blood 
stream infections, 
urinary tract infections 
 
 
 
   
-vs 3rd gen.cephalosporins 
 
85 
69 
6/6 
2/6 -vs carbapenems 
2-82 
Staphylococcus aureus 
0-68 
 
Wound infections, blood 
stream infections 
 
   
-vs methicillin “MRSA” 
 
42 3/6 0-36 
 
Table 2 Risk of death is higher in patients infected with drug resistant bacterial strains 
(WHO, 2014)  
Name of bacterium/ 
resistance 
 
Outcome (number of studies included)                       Deaths (%)  
 Patients with 
resistant strains 
Escherichia coli 
Patients with 
non-resistant strains 
-vs 3rd gen. cephalosporins 
-vs fluoroquinolones 
 
 
Bacterium attributable mortality (n=4) 
 
Bacterium attributable mortality (n=1) 
 
  
23.6 12.6 
0 
Klebsiella pneumoniae 
0 
-vs 3rd gen.cephalosporins 
-vs carbapenems 
 
Bacterium attributable mortality (n=4) 
    
Bacterium attributable mortality (n=1) 
 
 
  
10 
27 
10.1 
Staphylococcus aureus 
13.6 
-vs methicillin “MRSA” 
 
 
 
 
 
 
Bacterium attributable mortality (n=46) 
  
26.3 16.9 
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1.2 Antibiotic targets and development  
All organisms share a large number of common traits, such as cellular 
structure and metabolism, but, due to millions of years of evolution in some 
cases, also differ greatly. In particular, microorganisms have evolved unique 
cellular structures and metabolic properties as compared to eukaryotes that 
have potential to serve as targets for antibiotics. Currently, antibiotic 
development has targeted the four major metabolism pathways of DNA 
synthesis, RNA synthesis, protein synthesis and cell wall synthesis (Kohanski 
et al. 2010; Lewis 2013). Antibiotics have been developed to target bacteria 
specific proteins and substrates as shown in Figure 1. 
 
Figure 1. Antibiotics primarily target bacterial metabolism pathways (Lewis 2013).  
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Since the first antibiotic, penicillin, was discovered in 1929, dozens of naturally 
occurring antibiotics have been identified. As their underlying mechanisms of 
actions are deciphered, the drug–target interactions have been determined. 
This has led to the development of more novel artificial antibiotics via 
molecular modification of preexisting antibiotics. These efforts have greatly 
enhanced treatment in clinical practices. However, despite the increasing 
prevalence of drug resistance, the research and development for new 
antibiotics has almost halted. This is evident in the fact that there have been no 
major novel types of antibiotics developed in the last two decades (Figure 2). 
The antibiotic candidates currently in the pipeline are variations of previous 
antibiotics and, due to the similarity between the antibiotic structures and their 
targets, are likely to provoke new resistance (Carlet et al. 2012; Spellberg et al. 
2004). Thus, we are heading towards a post-antibiotic era in which common 
infections and minor injuries will be fatal. Therefore, the discovery of new 
antibiotics with novel antimicrobial mechanisms of action has become a matter 
of great urgency.  
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1.3 Drug resistance mechanism 
 
Figure 2. Timeline of discovery of distinct classes of antibacterial drugs (Higgins 2011).   
Evolution occurs naturally when microorganisms replicate themselves 
erroneously or exchange traits under selective pressure. Drug resistance has 
evolved in nature since ancient people started to use herb medicine well 
before the antibiotics era. Phylogenetic researches reveal that some classic 
resistant genes such as metallo-β-lactamases originated more than two billion 
years ago (Garau et al. 2005). Drug resistance is now widely spread all over 
the world because of antibiotic abuse and inadequate infection control 
practices.  
Antibiotics inhibit or alter essential cellular functions in bacteria by selective 
pressure. Antibiotic abuse, especially the improper administration of antibiotics 
below sufficient dosage, accelerates drug resistance. The major strategies 
6 
used by bacteria against antibiotics have been reported and are well 
understood (Figure 3). A possible strategy is antibiotic destruction. β-lactam 
antibiotics, such as penicillin, can be hydrolyzed by bacteria bearing the ESBL 
gene coding for a β-lactamase. Bacteria also use mutations to overcome 
antibiotics. Streptomycin resistance requires special mutations within the 
bacterial 30S ribosomal protein RpsL (Alekshun and Levy 2007). Another 
resistance mechanism involves reducing the accumulation of antibiotics by 
decreasing drug permeability or active pumping out. An example is 
AcfAB-TolC (Alekshun and Levy 2007) that could actively pump out multiple 
antibiotics with targets located inside cells. Furthermore, susceptibility of 
bacteria to antibiotics is highly related to the bacterial stage. Non-growing cells 
after the log exponential phase are relatively more tolerant to antibiotic 
treatments. The underlying mechanism is still largely unknown, but might be 
caused by the absence of active targets for antibiotics in non-growth cells 
(Kumar et al. 2013).  
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Figure 3. Bacterial cells employ multiple mechanisms to overcome antibiotics
1.4 Source distribution and physiological roles of antimicrobial 
peptides (AMPs) 
 (Alekshun 
and Levy 2007).   
AMPs have been highlighted because of their potential to solve the drug 
resistance problem. AMPs are part of the ancient, nonspecific innate immune 
system in many organisms. AMPs represent a universal feature of systematic 
defense for all life forms and are found in various organisms ranging from 
bacteria to plants and animals (Jenssen et al. 2006).  
The fruit fly is a model organism for invertebrates and has been the main 
subject of AMP studies (Engstrom 1999). Invertebrates lack an adaptive 
immune system found in vertebrates. Thus, AMPs are more important in 
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invertebrates than in vertebrates. The innate immune system seems very 
effective because the fruit fly can survive in hostile environments where 
pathogenic microorganisms thrive. The main types of AMPs in vertebrates are 
defincins and cathelicidins, which are characteristic of a conserved 
N-terminate or a conserved disulfide bridge crosslink (Jenssen et al. 2006). 
Amphibian skin glands contain elevated levels of AMPs. Up to 500 AMPs have 
been discovered from different amphibian species (Rinaldi 2002). Besides 
their function against infection, AMPs in bacteria also act as competition 
regulators. Bacteria secrete AMPs to kill other microorganisms that compete 
for nutrients in the same environment (Chatterjee et al. 1992; Klaenhammer 
1988).       
Plant AMPs always contain multiple disulfide bonds which bring a great 
obstacle for their production in bacteria, yeast or other organisms (Hammami 
et al. 2009) and thereby little attention has been drawn to plant peptides. Plant 
AMPs are mainly divided into 8 classes: snakin, defensin, thionin, knottin, 
hevein-like, cyclotide, impatiens and lipid-transfer. These are important in 
defending plants against bacteria, fungi, viruses and even parasites, though 
the production of secondary metabolites remains the main antimicrobial 
defence strategy in plants in most cases (Hammami et al. 2009). Along with 
their antimicrobial activity, they seem have more activity on the inorganic 
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defense such as frost, cold and dry (Hammami et al. 2009), and more and 
more attention has been drawn to understand their roles during development. 
1.5 Action of AMPs on bacteria 
The initial interaction between AMPs with their target microbes occurs through 
electrostatic attraction. Negatively charged membrane lipids seem to provide 
for a mutual and vigorous attraction to highly charged cationic antimicrobial 
peptides. Numerous studies have demonstrated that the charge of AMPs is 
highly associated with their membrane binding activity (Bessalle et al. 1992; 
Lee et al. 2013; Matsuzaki et al. 1997; Sato and Feix 2006; Yeaman and Yount 
2003). This view is also supported by the fact that AMPs from different species 
are conserved of highly positive charge (Gueguen et al. 2006; Seshadri 
Sundararajan et al. 2012; Wang et al. 2009). Given the facts that electrostatic 
forces exist in long distance range and that interactions between lysine or 
arginine with phosphate groups in lipid bilayers are particularly strong, 
electrostatic interactions likely drive the initial attraction between lipids and 
AMPs (Mavri and Vogel 1996). 
The event that follows the initial binding is a transition stage where the 
peptides dramatically increase their affinity towards the membrane by altering 
their geometric conformation; a self-promoting association or multimerization 
would occur and peptides are positioned perpendicular to the membrane 
(Huang 2000; Prado Montes de Oca 2013; Yeaman and Yount 2003). This 
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phenomenon is supported by oriented circular dicroism (OCD) studies on the 
orientation of peptides on the membrane surface. Most of these peptides are in 
alpha-helix form. The alpha-helices are oriented parallel to the membrane 
surface initially, but are then re-oriented perpendicular to the membrane when 
the threshold concentration is reached. The membrane finally develops a 
transmembrane deficiency, which could either be a hole or a channel, after the 
transition stage. Different speculations have been described for this stage, 
namely, barrel-stave, toroid-pore, and carpet theories (Prado Montes de Oca 
2013; Wimley 2010; Yeaman and Yount 2003). 
The barrel-stave model suggests that the peptides binding to the membrane 
surface would push the local lipids aside. The peptide would then be inserted 
into the bilayer along with a conformational change that orients the 
hydrophobic residues of peptides in such a way that they face the lipids. The 
hydrophilic residues form a pore lining. The barrel-stave pore only consists of 
peptides. Thus, the peptides require a sufficient length to expand across the 
bilayer. Similar to the barrel-stave model, the toroid-pore model uses peptides 
to form the pore lining. However, the toroid-pore model is different from the 
barrel-stave one because in the toroid-pore model, the pore lining forms a 
mosaic with both headgroups from the peptide and lipid. The carpet theory is 
much simpler than the previous two theories because the peptide does not 
have to intercalate or align with the lipids. The continuous accumulation of the 
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peptides on the membrane surface would displace the lipids and finally disrupt 
the membrane. This mechanism can be observed in the segmentation and 
fragmentation of the lipid membrane by most surfactants.  
Aside from the three classic models mentioned above, many experiments 
suggest that an external electric field can open the membrane transiently 
(Teixeira et al. 2012). A comprehensive practice in previous studies is to 
introduce DNA molecules into bacterial cells using electroporation. A minimal 
voltage of ~1 V is required to form pores on the cell membrane when a short 
pulse is applied. However, this threshold would be significantly decreased to 
~0.2 V when the electric field is constant or lasting. Thus, the electroporation 
theory is an alternative to the stable channel/pore complex formation 
suggested by carpet barrel or toroid theory. Electroporation theory suggests 
that a transient pore is formed because of an external electric field, which is 
generated from peptide binding. A highly positively charged peptide binds to 
the outer membrane, thereby creating an electric field that points toward the 
inner plasma. The membrane breaks and forms a transient channel when it 
reaches a threshold that allows the translocation of the peptide-anchored 
lipid-raft into the inner lipid leaflet. The leakage of inner molecules, such as 
ions and proteins, occurs along with the translocation of the peptide–lipid raft. 
The external potential falls below the threshold again, which results in the 
closure of the transient channel. Slightly different from electroporation theory, 
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sinking-raft theory suggests that the transient pore formation was due to mass 
imbalance caused by peptide preferential binding by self-association or 
self-assembly (Teixeira et al. 2012).  
 
Figure 4. AMP mechanisms in the formation of transmembrane pores (Teixeira et al. 
2012). A) barrel-stave model; B) carpet model; C) toroid-pore model; D) 
electroporation model; E) sinking-raft model.  
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1.6 Bacterial cell wall and membrane offer selective targeting 
for AMPs 
All biomembranes are composed of a fluid mosaic of amphiphilic substances, 
such as lipids and protein. However, biomembranes significantly differ in terms 
of the presence of lipid species and their composition in different organisms to 
which AMPs exert different binding affinities. A possible source for AMP 
selectivity is the charge difference created by the lipid composition and 
architecture within the membrane (Epand et al. 2007; Nizet 2006; Spector and 
Yorek 1985). Biomembranes contain phosphatidylcholine (PC), 
phosphatidylethanolamine, and sphingomyelin, which are general zwitterionic 
lipids without any net charge. The incorporation of ionic lipids, including PS, 
PG, and cardiolipin, can create a negative charge on the membrane surface, 
which in turn attracts AMPs. Enriched membranes in acidic lipids are 
commonly found in bacteria. The proportion of PG and cardiolipin exceeds 
50% of the total membrane lipids for some species, such as Escherichia coli 
(Epand et al. 2007). By contrast, ionic lipids are typically present at extremely 
low levels (generally less than 5%) in mammalian cells. Mammalian 
membranes are also structured asymmetrically with most of their acidic lipids 
aligned at the inner leaflet facing the cytoplasm. Thus, the charged moiety is 
no longer exposed to the external environment. 
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Outside of the plasma membrane, bacteria use a particular envelope known as 
a cell wall to wrap their fragile plasma membrane. Such a structure improves 
bacterial compatibility to environments with extreme levels of salt, pH, and 
organic solvent (Yeaman and Yount 2003)
In Gram-positve bacteria, the cell wall composition is much simpler and mainly 
consists of multiple layers of peptidoglycan interspersed with teichoic acids. 
The teichoic acids run perpendicular towards the peptidoglycan sheets and are 
unique to Gram-positive cell walls (Figure 5A). 
. Based on Gram-staining method, 
bacteria are generally divided into two classes—the Gram-positive and 
-negative bacteria. Except the peptidoglycan murein which is a basic element 
for all bacterial cell walls, Gram-negative and -positive bacteria differ greatly 
from each other. 
Different from Gram-positive bacteria, the cell wall of Gram-negative bacteria 
is much complicated. Outside of the peptidoglycan layer, there is an extra layer 
of lipid membrane termed “outer membrane” for Gram-negative bacteria. This 
outer membrane is linked to the inner peptidoglycan by lipoproteins and is 
anchored with lipopolysaccharide (LPS) at the outer leaflet (Figure 5B). 
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Figure 5. Structures of Gram-positive and –negative bacterial cell envelopes 
(mol-biol4masters.masters.grkraj.org, by Dr. Kenneth Todar). A) Structure of 
Gram-positive bacteria cell wall. The wall is relative thick and consists of multiple layers of 
peptidoglycan with teichoic acids running perpendicular to the peptidoglycan sheets. B) 
Structure of Gram-negative bacteria cell wall. The wall is relative thin and contains an 
extra layer of outer membrane with LPS anchored at the outer leaflet.  
 
A 
B 
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This unique envelope is also negatively charged either by teichoic acid or LPS 
for Gram-positive and Gram-negative bacteria. These components can attract 
highly positively charged AMPs. These AMPs aggregate on the cell surface 
before inserting into the membrane. Several findings suggest that LPS induces 
AMP targeting.  
The above mentioned perspectives show that bacteria are considered 
electrostatically more attractive for positively charged AMPs. Besides, the 
thermomechanical lipid bilayer properties, which significantly affect membrane 
stability, are regulated by the presence or absence of lipid species and their 
lipid composition. The most comprehensive example is cholesterol, which 
comprises up to 50% of the lipids in the mammalian cell membrane, but is 
rarely present in bacterial membrane. The cell membrane becomes packed, 
but still exhibits good fluidity in the presence of cholesterol (Yeagle 1985), 
thereby preventing insertion or breakage. 
Table 3. Representative membrane lipid composition of Gram-negative and 
Gram-positive bacteria, fungi and mammalian erythrocytes (Fischer 1994; Morein et al. 
1996; Ratledge and Wilkinson 1988; Teixeira et al. 2012).  
 
 Present in trace or undetermined amounts. * Lipids composition in exponential growth phase. ** 
Inconsistent data 
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1.7 Structure vs. efficacy 
The disulfide bridges, generally present in the AMP sequence, are closely 
related to the AMP antimicrobial activities. Spatial restraint by disulfide bonds 
provides the prerequisite for AMPs to fold into the correct conformation (Fan et 
al. 2013; Jenssen et al. 2006). AMPs exert membrane activity by conformation 
transition.  
AMPs represent a unique and diverse group of proteins with a length of 12 to 
50 amino acids. These AMPs are divided into subgroups based on their 
residue composition and structure. AMPs contain two or more basic amino 
acids. Their secondary structures follow four patterns, namely, α-helix, β-sheet, 
loop/coil, and extended (Jenssen et al. 2006). Most AMPs dissolve in aquatic 
buffer with a random structure, but adopt a special 3D structure upon 
partitioning into biological membranes. Within this special structure, 
hydrophobic residues are concentrated on one side, whereas hydrophilic 
residues are found on the other side. This amphipathicity allows AMPs to 
partition into membranes.  
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Figure 6. Structural classes of antimicrobial peptides (Jenssen et al. 2006). Examples of 
Different AMPs structures are given by (A) Mixed structure of human β-defensin-2 (PDB 
code 1FQQ) and (D) rabbit kidney defensin-1 (PDB code 1EWS); (B) looped thanatin 
(PDB code 8TFV); (C) β-sheeted polyphemusin (PDB code 1RKK); (E) α-helical 
magainin-2 (PDB code 2MAG); (F) extended indolicidin (PDB code 1G89).   
1.8 Objective of this research 
The antimicrobial peptide Ib-AMP4 has two disulfide bonds. Ib-AMP4 has been 
isolated from Impatiens balsamina and exhibits broad antimicrobial activity 
against plant pathogens. In this study, we aimed to do the following: 1) to 
produce recombinant Ib-AMP4 in large amounts by Escherichia coli 
expression and purification; 2) to estimate Ib-AMP4‘s potential as a clinical 
treatment and its combination potential with traditional antimicrobial agents; 3) 
to determine the target of Ib-AMP4 and the underlying mechanism for Ib-AMP4 
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to exert a rapid bactericidal effect; 4) to investigate the role of the cell wall and 
membrane during Ib-AMP4 targeting; and 5) to show the effect of cations, 
particularly divalent Ca2+, during the antimicrobial process of Ib-AMP4.  
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Chapter 2. Materials and methods 
2.1 Reagents and Chemicals 
Restriction enzymes HindIII, KpnI, ligase, and recombinant enterokinase (rEk) 
were purchased from New England Biolabs (Beverly, MA, USA). Tryptone and 
yeast extract were sourced from GE Healthcare Biosciences (Pittsburgh, USA). 
Ampicillin and isopropyl β-D-1-thiogalactopyranoside (IPTG) were obtained 
from Sigma (Sigma-Aldrich Chemie GmbH, Munich, Germany).  
DOPC and DOPG from Avanti (Avanti Polar Lipids, Alabaster, Alabama) were 
dissolved in chloroform/methanol (9:1) at 2.5 mg/ml and used as stock 
solutions. Calcein, cholesterol, and BSA (lyophilized powder) were purchased 
from Sigma (Sigma-Aldrich, Munich, Germany). Deep rough mutant LPS (LPS 
Re) was extracted from Escherichia coli strain F515, whereas LPS Ra was 
purified from the bacterial rough strains of Salmonella enterica (Galanos et al. 
1969). All chemicals and organic solvents used in this study were of analytical 
grade or higher. 
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Figure 7. Structures of DOPC, DOPG and cholesterol. DOPG and DOPC share a very 
similar structure with only small differences existing at the headgroup, which introduced a 
negative charge to the DOPG. Cholesterol is a truly neutral compound. 
2.2 Buffers 
MilliQ water was used to prepare all aqueous solutions. The following buffers 
were used for Ib-AMP4 purification: lysis buffer (50 mM Tris, 200 mM NaCl, 
and 1 mM EDTA; pH 8.0), loading buffer (50 mM Tris and 200 mM NaCl; pH 
8.0), washing buffer (50 mM Tris, 200 mM NaCl, and 5 mM imidazole; pH 8.0), 
and elution buffer (50 mM Tris, 200 mM NaCl, and 0.25 M imidazole; pH 8.0). 
Cleavage buffer (25 mM Tris, 50 mM NaCl, and 2 mM CaCl2; pH 8.0) was 
used for rEk cleavage. The following buffers were used in the mechanism 
study: calcium-free buffer (10 mM HEPES, and 150 mM NaCl; pH 7.4) and 
calcium-loaded buffer (10 mM HEPES, 150 mM NaCl, and 50 mM CaCl2
2.3 Bacteria, cells, and plasmids 
; pH 
7.4). 
Escherichia coli JM109 and BL21/DE3 were purchased from NEB (New 
England Biolabs, Beverly, MA, USA), and the plasmid pET32a bearing a lac 
promoter for the expression was bought from Novagen Company (Novagen, 
Madison, Wisconsin, USA). Adenocarcinomic human alveolar basal epithelial 
cell line A549 was purchased from ATCC. 
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The antimicrobial activity of Ib-AMP4 was evaluated by testing its MIC against 
29 clinical isolates and 20 standard reference bacteria, including MRSA 
and ESBL-
2.4 Protein expression 
producing E. coli. These strains were human clinical isolates: (1) 
Gram-negative bacteria: Acinetobacter calcoaceticus, Proteus vulgaris, 
Proteus mirabilis, Enterobacter cloacae, Enterobacter aerogenes, Escherichia 
coli, Serratia marcescens, Pseudomonas stutzeri, Pseudomonas aeruginosa, 
Klebsiella oxytoca, Klebsiella aerogenes, Citrobacter freundii; (2) 
Gram-positive bacteria: Bacillus megaterium, Bacillus subtilis, Enterococcus 
faecium, Enterococcus casseliflavus, Micrococcus luteus, 
Staphylococcus haemolyticus, Staphylococcus epidermidis, Staphylococcus 
aureus, Staphylococcus oralis, Staphylococcus saprophyticus, Streptococcus 
agalactiae, Streptococcus pyogenes and Streptococcus pneumoniae. The 
clinical isolates were obtained from the Center of Medical Laboratory of 
Zhongda Hospital, Southeast University, China. The standard reference 
bacteria were purchased from ATCC.  
2.4.1 DNA design, plasmid design 
The Ib-AMP4 DNA containing an rEk cleavage site with flanking HindIII and 
KpnI sites (ATCGGGTACC GATGACGATG ACAAACAGTG GGGTCGTCGT 
TGCTGCGGTT GGGGTCCGGG TCGTCGTTAT TGCCGTCGTT 
23 
GGTGCTAATA AAAGCTTATC G) was synthesised by GeneRain Company 
(Shanghai, China). The synthesized DNA was inserted into the plasmid 
pET32a.  
2.4.2 Construction of plasmid pET32A-Trx-Ib-AMP4 
Ib-AMP4 DNA and the plasmid pET32a were digested by HindIII and KpnI 
separately and then ligated by DNA ligase. We followed the protocols in 
molecular cloning (Green and Sambrook, 3rd edition 2001) and Novagen 
manuals. The resulting recombinant plasmid was transferred into Escherichia 
coli JM109 for screening on plates with ampicillin. DNA was isolated from 
positive clones and sent for sequencing to confirm the correct sequence of the 
construct. 
2.4.3 Preparation of Escherichia coli DH5a and BL21 competent 
cells and transformation 
Competent cells were prepared using the classic calcium chemical method to 
introduce the plasmid into the Escherichia coli cells. This method is simple to 
operate, requires no special instruments, and yields good transformation 
efficiency. The procedure was performed as follows: 
1. Frozen bacteria were activated from -80 °C by drawing the bacteria on a 
dish plate containing fresh solid LB medium. This set-up was incubated 
overnight. 
24 
2. A single colony from the LB plate was inoculated into 4 ml of fresh LB liquid 
medium and incubated overnight. Ampicillin was added as a negative control.  
3. The overnight cell culture was inoculated into 100 ml of the fresh medium at 
a ratio of 1:100 and incubated for ~2 h with an OD600
4. Cells were retrieved by centrifugation at 4,000 rpm and at 4 °C. Cell pellets 
were resuspended in 20 ml cold buffer containing 0.1 M CaCl
 between 0.2 and 0.3. 
2
5. The cells were stored in ice for 30 min. 
. 
6. The cells were retrieved by centrifugation, and the pellets were resuspended 
in 1 ml 0.1 M CaCl2
7. Approximately 100 μl of the cell suspension was pipetted in each 
micro-centrifuge tube. 
. 
8. The competent cells were ready for usage or were stored at -80 °C for one 
month.   
The constructed plasmid was introduced into the competent cells following the 
standard molecular cloning manual. An aliquot of the competent cells (100 μl) 
was obtained from ˗80 °C storage and thawed on ice. After adding 0.5 μl of 
200 μg/ml plasmids, the competent cells were immediately translocated into a 
40 °C water bath for exactly 45 s. The cells were then maintained on ice for 
another 30 min and spread on a dish plate with fresh medium containing 100 μ
g/ml ampicillin for screening.  
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2.4.4 Expression of pET32A-Trx-Ib-AMP4 
Escherichia coli cells containing pET32a-Trx-Ib-AMP4 were seeded and grown 
in 1 ml LB broth (10 g peptone, 5 g NaCl, and 5 g yeast extract/l LB broth) 
overnight. The overnight culture was trans-inoculated into flasks with 250 ml 
fresh LB medium with 0.01% ampicillin. Flasks were shaken at 200 rpm at 
37 °C overnight. Induction with 1 mM IPTG was performed at 28 °C for 7 h.  
2.5 Purification 
2.5.1 Cell lysis 
The cells were collected after expression induction by centrifugation at 
4,000 rpm for 10 min. Cells were resuspended in a lysis buffer. The cell 
suspension was subjected to two cycles of thaw-freeze before ultrasonication 
to lyse the cells sufficiently. Ultrasonication was performed in an ice bath at 
300 W for 40 min with an impulse of 5 s/5 s. The cell suspension cleared up 
after the cells were broken. The insoluble cellular debris was removed by 
centrifugation at 8,000 rpm for 25 min. The supernatant was collected for 
Ni-affinity chromatography.     
2.5.2 Ni-Affinity chromatography 
Soluble proteins were retrieved by collecting the supernatant after cell lysis, 
and the supernatant was applied to a nickel affinity column (Madison, 
Wisconsin, USA) that was pre-equilibrated with a loading buffer. Nonspecific 
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bound impurities were eliminated by a washing buffer. The final process 
involved the retrieval of the bound protein by applying an elution buffer to the 
column. The steps of the procedure were monitored by an ultraviolet 
spectrophotometer 
2.5.3 rEk cleavage 
with a wavelength of 280 nm. 
The elution from Ni-Affinity chromatography mainly contained the expressed 
fusion protein of Trx-Ib-AMP4, with Ib-AMP4 fused with Trx. The fusion partner 
of Ib-AMP4, Trx, was removed by enterokinase cleavage to obtain the pure 
peptide of Ib-AMP4. The elution was first dialyzed against a cleavage buffer to 
complete the rEk cleavage. After dialysis, the protein solution was 
concentrated to a concentration of 4 mg/ml by ultrafiltration (10,000 kD pore 
size, Millipore Corporation, Billerica, MA, USA) followed by rEk digestion. 
Enterokinase was added at a ratio of 5 units of rEk per 2.5 mg fusion protein. 
The cleavage was performed at 37 °C for 18 h. The proteins after rEk cleavage 
were examined by SDS–PAGE. 
2.5.4 G-25 size exclusion chromatography 
The proteins were filtered through a 0.5 micron membrane after rEk cleavage 
and subsequently applied to a G-25 molecular filter column (80 cm × 5 cm2). 
Pure water was used as washing and elution buffer. The flow was maintained 
at a constant rate of 5 ml/min. The loading amount of digested protein was 
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fixed at 5 ml for each purification cycle. Fractions with OD280 absorption were 
collected and examined by SDS–PAGE, HPLC, and mass spectrometry 
(MALDI-MS). The fraction containing Ib-AMP4 was lyophilized and stored at 
-20 °C.  
 
Figure 8. Scheme of Ib-AMP4 purification. The fusion protein carried 6 X His tag was 
mainly expressed in a soluble form. The fusion protein could be easily retrieved by nickel 
affinity chromatography. After rEk cleavage and G-25 sephadex chromatography, 
Ib-AMP4 was separated from its fusion partner of Trx.  
2.6 Activity test 
2.6.1 Activation and stability 
The lack of post-translational modification in Escherichia coli cells called for an 
extra step to oxidize the disulfide bonds of Ib-AMP4 after purification. In order 
to optimize the condition for oxidation, three lyophilized samples were 
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processed under different temperature with or without a adding of 5 µg/ml 
H2O2. 
2.6.2 Minimal inhibitory concentration (MIC) 
The activation of Ib-AMP4 samples was evaluated by comparing its MIC 
against Staphylococcus aureus ATCC 25923. Duplicate wells were used each 
time and the results were recorded after the plates were incubated at 37 °C for 
24 h.  
MIC tests were carried out according to the NCCLS broth microdilution method 
(Ferraro 2005). Briefly, bacteria were seeded in 1 ml medium and shaken 
overnight. A dilution was prepared with an OD600 of 0.8 from this culture, 
which was further diluted into a fresh medium (5 : 1000; v/v) for micro-volume 
plate assay on 96 well plates. The peptide was diluted across rows by two-fold 
serial dilutions. The results were recorded after the plates were incubated at 
37 °C for 24 h. Experiments were run in duplicates and each test was repeated 
independently. Ampicillin and 0.001% H2O2 
2.6.3 Time killing curve 
were used as positive and 
negative controls, respectively. 
Bactericidal kinetics were determined by counting viable bacteria after 
treatment with 2 X MIC of Ib-AMP4. Briefly, Staphylococcus aureus 
ATCC25923 was seeded and grown in fresh dextrose-tryptone-broth (DTB) 
medium overnight. The overnight culture was then transferred into fresh DTB 
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containing 20 µg/ml Ib-AMP4. Every 2 min after incubation 10 μl aliquots of the 
culture medium were diluted into 990 μl ddH2
2.6.4 Two-drug combination and FICI 
O, and 100 μl of the dilution were 
immediately plated on sheep blood agar plate (37°C). The viable colonies 
were counted after incubation of 24 h. 
The classic checkboard method  was used in the combination tests of 
Ib-AMP4 with silver nitrate, thymol, oxacillin, EDTA, vancomycin, or other 
antimicrobial agents. A medium serial was pre-supplemented with different 
concentrations of an antimicrobial agent, such as EDTA or vancomycin, 
ranging from 0× MIC to 1× MIC to a given bacterium. The MICs of Ib-AMP4 
against the corresponding bacteria were measured in the medium serials. 
Another method used in the combination tests was similar to the above 
mentioned one, except that Ib-AMP4 was pre-supplemented into the medium. 
Only three concentrations (i.e., 0.2x, 0.4x, and 0.6x MIC) of Ib-AMP4 were 
tested on corresponding bacterium via several combinations to economize on 
Ib-AMP4 usage .  
FICI was introduced to estimate the combination effect and analyze the results 
of the two-drug combination. FICI is a summary of each individual’s 
contribution to the combination and could be expressed as follows (Elion et al. 
1954; Hall et al. 1983): 
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Based on FICI, the combination was subjected to three patterns: i) antagonistic 
effect with FIC > 2.0; ii) additive effect with 0.5 < FIC < 2.0; and iii) synergistic 
FIC < 0.5.  
2.6.5 Cytotoxicity in cancer cells 
A suspension of A549 cells (~10,000 cells/ml) was prepared in fresh DMEM 
medium containing 10% bovine serum then 100 μl were added to each well of 
a 96-well plate. The plate was incubated at 37 °C plus 5% CO2
2.6.6 Heamolysis activity 
 until the cell 
density reached about 30% of each well, then 100 μl fresh media containing 
serial dilutions of Ib-AMP4 ranging from 400 to 25 µg/ml were added. 
Afterwards, the plate was incubated for another 24 h before carrying out the 
MTT assay as described before (Plumb 2004). Three duplicates were 
analyzed and the test was repeated for three times. 
The haemolysis assay was carried out as previously described (Shimojo and 
Iwaoka 2000). Briefly, a volume of 1 ml heparinised sheep blood was washed 
6 times with 8 X volume of saline; then the blood cells were retrieved and 
resuspended in 4 ml saline for use. The haemolysis assay was carried out in a 
96-well plate loaded with 100 µl blood cell suspension per well. Afterwards, 
100 µl Ib-AMP4 (400 µg/ml) were then added to the first well and diluted 
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twofold across rows. The plate was then incubated at 37 °C for 45 min followed 
by centrifugation. A volume of 50 µl supernatant was taken from each well and 
measured photometrically at 540 nm to reveal haemoglobin that had been 
released from erythrocytes. Haemolysis caused by 0.5 mg/ml SDS and 0.9% 
saline was defined as 100% and 0% activity, respectively. Three duplicates 
were analyzed and the test was repeated for three times. 
2.6.7 Surfactant activity 
Surfactant activity of Ib-AMP4 was evaluated by measuring the surface tension 
of pure water in the presence of different concentrations of Ib-AMP4 ranging 
from 5 μg/ml to 1 mg/ml. This measurement was carried out with a Langmuir 
film balance (Kibron, Helsinki, Finland).                                                                                 
2.7 Study of model of action with membrane models 
2.7.1 Liposome/vesicle preparation 
Calcein-encapsulated small unilammellar liposomes were prepared by the 
extrusion method (Balhara et al. 2013). A lipid film was dried from a 
chloroform/methanol solution under a stream of nitrogen followed by 3 h of 
vacuum drying. The dry film was subsequently rehydrated with 80 mM calcein 
in HEPES buffer (pH 7.4) containing 10 mM HEPES and 150 mM NaCl 
followed by extrusion for 21 times through a polycarbonate membrane of 
200 nm pore size. The yielded homogenous liposomes were collected and 
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passed through a PD-10 column (GE Healthcare, Freiburg, Germany) to 
remove the free calcein. The elution fractions from chromatography were 
prepared for the calcein leakage assay. 
Calcein-free unilammellar DOPC liposomes were prepared using the above 
mentioned method, but were rehydrated with a HEPES buffer without calcein. 
LPS-Re vesicles were prepared by sonicating 1 mg/ml LPS in HEPES buffer 
for 60 min. The vesicle size was checked by DLS. 
Four different types of liposomes were prepared to estimate the effect of 
DOPG and cholesterol during membrane disruption. Their molar composition 
were as follows: DOPC (100%) as control; DOPC/cholesterol (7:3) to mimic 
blood cells; DOPC/DOPG (85:15) to mimic Staphylococcus aureus; and 
DOPC/DOPG (40:60) to mimic E. coli.  
2.7.2 Liposome leakage assay 
Liposomal leakage caused by Ib-AMP4 was studied by monitoring the release 
of calcein loaded  
liposomes (Balhara et al. 2013). Calcein was self-quenched at a high 
concentration inside the liposome, but showed an increase in fluorescence 
intensity after being released from the liposome when the membrane bilayer 
became leaky. 
Black plate (Ibidi GmbH, Martinsried, Germany) was incubated overnight 
before usage with HEPES buffer containing 5% BSA to block the unspecific 
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binding sites. A concentration serial of Ib-AMP4 in the HEPES buffer was 
initially prepared in wells by diluting twice and mixing with 50 μl liposome 
solution. After mixing, the plate was immediately analyzed using a 
fluorescence reader (Tecan, Mainz, Germany) with exiting and emission 
wavelengths of 295 and 325 nm, respectively. The fluorescence intensity was 
recorded over time. 
2.7.3 Giant unilamellar vesicle (GUV) preparation 
The GUV was prepared by electroformation with indium thin oxide (ITO) 
coated slides as reported previously (Bi et al. 2013; Herold et al. 2012). The 
ITO slides were cleaned by sonication in ethanol, isopropanol, and deionized 
water thrice, followed by annealing for activation. Annealing was performed by 
placing the slides in a heating chamber of 150 ℃ for 20 min and then cooling 
down to room temperature (RT) (Morales-Penningston et al. 2010). The slides 
were always placed with their ITO-coated sides exposed to the air to avoid 
contamination.  
The lipid thin layer was coated onto one slide by the flat-coating method (Bi et 
al. 2013; Estes and Mayer 2005). Approximately 300 μl of 2.5 mg/ml DOPC in 
chloroform was dropped onto a slide surface. A needle was used to carefully 
spread the solution back and forth. Before the lipid dried, the slide was placed 
in the center of a horizontal centrifuge and centrifuged at 1,000 rpm for 10 min 
to homogenize the film. The slides were placed in a vacuum for another 2 h. 
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After the solvent evaporated completely, two slides were assembled in an 
electroformation chamber with their ITO coated sides facing each other. The 
chamber was then filled with 300 mM sucrose. A sinusoidal AC electric field of 
10 Hz and 1.5 V was applied for 3 h to form GUVs. 
2.7.4 Time elapse photography 
GUV liposome solution (30 μl) mixed with 120 μl glucose (300 mM) was 
injected into the sample slide chamber (Ibidi GmbH, Martinsried, Germany). 
The mixture was incubated for 10 min to allow the precipitation of the GUVs. 
Ib-AMP4 (400 μg/ml) at 50 μl was gently injected from the right side. The 
diffusion of peptide started from the right side. A dynamic gradient of the 
peptide concentration was introduced onto the GUV sample. The dynamic 
change in GUVs was monitored under a microscope (Keyence, Mannheim, 
Germany) equipped with a 10x ocular and a 40x objective. 
2.7.5 Surface pressure and potential of the monolayer 
2.7.5.1 LPS-Re isotherm and peptide injection 
A monolayer was obtained by gently spreading LPS onto the aqueous surface 
with a Hamilton syringe followed by incubation for 20 min to allow evaporation 
of organic solvents. 
Surface tension-molecular area (π-A) and surface potential-molecular area 
(P-A) isotherms were recorded with a Langmuir film balance (Kibron, Helsinki, 
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Finland). The stock solution of LPS-Re (2 mg/ml in CHCl3/CH3OH (9/1 in v/v)) 
was spread onto the subphase. After the complete evaporation of the solvent 
(20 min), the film was compressed at a constant speed of 4.5 Å²/chain/min. 
Two types of buffer subphases (pH 7.4) were used to study the effect of Ca2+ 
ions, as follows: (i) a “Ca2+-free” buffer containing 5 mM HEPES and 100 mM 
NaCl and (ii) a “calcium-loaded” buffer containing 50 mM CaCl2
The target molecular area was set to ~140 Å², corresponding to a surface 
pressure of ~17 or ~25 mN/m for calcium-free or calcium-loaded subphases, 
respectively, to compare the interaction between the peptide and LPS 
molecules at the same molecular area. When the target molecular area was 
reached, the monolayer was allowed to equilibrate for 20 min before peptide 
injection. The final concentration of the injected peptide was 2 μM.  
. 
2.7.5.2 Lipid isotherm 
Compression (π-A) isotherms for lipids at 20 ± 1 °C on calcium-free and/or 
calcium-loaded buffers were conducted with a KSV NIMA Langmuir system 
(Biolin Scientific, Stockholm, Sweden) equipped with two Delrin barriers, a 
Teflon trough with a surface area of 86 cm2, and a Wilhelmy paper sensor. The 
procedure was nearly the same as that for the LPS isotherm with minor 
modifications. The amount of lipid was adjusted to achieve an initial surface 
pressure below 1 mN/m. π-A isotherms were obtained by compressing the 
monolayer with two movable barriers at a constant rate of 5 mm/min. 
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2.7.6 Quartz Crystal Microbalance with Dissipation (QCM-D) for 
LPS and DOPC 
Experiments using the quartz crystal microbalance with dissipation monitoring 
were performed at 25 ℃ using a QCM-D E4 system (Q-sense, Gothenburg, 
Sweden). The oscillation frequency shift (Δf) and the simultaneous energy 
dissipation change (ΔD) of the quartz crystal were recorded simultaneously. 
Changes in resonance frequency reflected the bound mass deposited on the 
surface of the quartz sensor, whereas changes in energy dissipation provided 
information on the roughness property of the adsorbed material (Dixon 2008). 
An Au-coated crystal was purchased from Q-Sense (Gothenburg, Sweden). 
The quartz was first cleaned with a mixture of H2O/NH3 (25%)/H2O2 
The procedure for the LPS-Re vesicle was almost the same, but was 
completed before LPS-Re adsorption. The quartz was first coated with 
octadecanethiol before the LPS-Re adsorption to provide a hydrophobic 
environment in which the LPS-Re would anchor. 
(30%) in a 
5/1/1 ratio at 70 ℃ for 10 min; subsequently, the quartz was rinsed with MilliQ 
water and dried under a stream of nitrogen (Makky et al. 2010). The quartz 
was assembled into the quartz chamber and initially equilibrated with a loading 
buffer for 20 min, followed by DOPC liposome injection. After the completion of 
DOPC liposome adsorption, the quartz was then rinsed and loaded with the 
Ib-AMP4 peptide solution.  
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2.7.7 Dynamic light scattering (DLS) 
The radius of the prepared liposome was measured by DLS with a Zetasizer 
Nano-S (Malvern Instruments, Ltd., Worcestershire, UK). A homogenous 
DOPC liposome with diameter of ~200 nm was prepared as described and 
diluted 200 times in HEPES buffer with a final lipid concentration of ~26 μM. 
An Ib-AMP4 peptide concentration serial was prepared in HEPES buffer and 
mixed with an equal volume of liposome. For each measurement, the cuvette 
was equilibrated for 5 min at 20 ℃. The final result was recorded as an 
average of three measurements. All measurements were performed with a 
constant lipid concentration of ~13 μM in the presence of different 
concentrations of Ib-AMP4 peptide ranging from 2 μM to 30 μM.  
2.7.8 Circular dichroism (CD) spectra 
CD spectra were measured with a J-715 spectrometer (Jasco Corporation, 
Essex, UK) using a 0.1 cm path length quartz cuvette at 20 °C from 190 nm to 
250 nm. All spectra were corrected by subtraction of the buffer spectra. The 
Ib-AMP4 concentration was fixed at 100 μM and supplemented with different 
amounts of liposome to obtain peptide/lipid ratios (P/L). The secondary 
structure was estimated with software provided by the manufacturer (Balhara 
et al. 2013). 
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2.7.9 Transmission electron microscope (TEM) 
The cell sample was prepared as reported previously (Wu et al. 2010). 
Log-phase ATCC 25922 Escherichia coli cells were collected by centrifugation 
and resuspended in MilliQ water containing 500 μg/ml Ib-AMP4. The cells 
were incubated for 20 min and retrieved by centrifugation at 4,000 g for 5 min. 
The cell pellet was collected and then processed by prefixation with 2.5% 
glutaraldehyde in a 0.2 M phosphate buffer (pH 7.3), postfixation in 0.5% 
osmium tetroxide in a Millonigs constant-osmolarity phosphate buffer (pH 7.4), 
and dehydration in graded ethanol solutions. The dehydrated cell pellet was 
embedded in medium Taab Resin and polymerized for 24 h at 60 ℃. Slices 
(50 nm) were prepared and stained with aqueous uranyl acetate and lead 
citrate. Stained slices were examined using JEM-1010 TEM (JEOL, Tokyo, 
Japan). 
2.8 Statistics 
All experiments were repeated at least three times. Similar results were 
obtained. The MIC values were expressed as concentration range. The other 
values were analyzed by Excel and SigmaPlot software and expressed as the 
mean value from independent repeats. 
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Chapter 3. Expression and purification of Ib-AMP4 in 
Escherichia coli*
3.1 Abstract 
 
AMPs represent a novel class of powerful natural antimicrobial agents. 
Ib-AMP4, which has two disulfide bonds, has been isolated from I. balsamina. 
Ib-AMP4 exhibits broad antimicrobial activity against plant pathogens. A large 
amount of Ib-AMP4 was required to study its potential as a clinical treatment. 
We presented the successful expression and purification of recombinant 
Ib-AMP4 from E. coli. An E. coli-specific gene for Ib-AMP4 was designed 
manually and inserted into a vector of pET32a for expression in Escherichia 
coli cells. After induction with 1 mM IPTG, a soluble fusion protein was 
expressed successfully. The Ib-AMP4 peptide was finally obtained with a 
purity of over 90% after nickel affinity chromatography, ultra filtration, 
enterokinase cleavage, and Sephadex size exclusion chromatography. Given 
the lack of posttranslational modification, the obtained peptide was activated 
by 5 µg/ml H2O2 
 
to form two disulfide bridges.  
 
                                            
* This chapter has been published as: “Fan, X., Schafer, H., Reichling, J., Wink, M., Bactericidal 
properties of the antimicrobial peptide Ib-AMP4 from Impatiens balsamina produced as a recombinant 
fusion-protein in Escherichia coli, Biotechnol J, 8 (2013) 1213-1220.” 
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3.2 Introduction 
AMPs can potentially be used to solve the drug resistance dilemma that has 
plagued global health in the last decade. AMP research has focused mainly on 
animal peptides rather than plant peptides because the latter have complex 
structures with multiple disulfide bonds. AMPs occur naturally in biological 
organisms, but at limited concentrations. AMPs have to be prepared in large 
amounts for use in laboratory research. To date, the most convenient and 
economic way of preparing AMPs is to express AMPs in prokaryotic cells. 
Given its well-characterized features, low cost, rapid replication, and simple 
manipulation, Escherichia coli has become the most popular organism for the 
prokaryotic expression of heterologous proteins (Samuelson 2010), even if 
some remaining issues, such as the post-transcriptional modification and 
disulfide bond formation, exist.  
Escherichia coli can express proteins encoded by a transformed plasmid, and 
such capability offers many choices for different purposes. The target protein 
can be expressed by different strategies, such as single or fusion expression 
and cytoplasm expression or secretion expression coupled with different 
purification strategies downstream. Given that AMPs are bactericidal, their 
production in recombinant bacteria is far from trivial. Inclusion body expression 
has been reported in several cases. Another strategy involves the production 
of inactive fusion proteins, which has been successfully applied to Escherichia 
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coli to obtain various peptides, from large antibody proteins of over 30,000 kD 
to triple peptides comprising three amino acids. This approach can also be 
adopted for the production of AMPs (Katoh et al. 2010; Li et al. 2012; Wu et al. 
2010).  
Ib-AMP4 with 20 amino acids was firstly extracted from the seeds of Impatiens 
balsamina (Balsaminaceae) together with three other analogues (Tailor et al. 
1997). In Ib-AMP4 (QWGRRCCGWGPGRRYCRRWC) the two intramolecular 
disulfide bonds are conserved. However, according to a later report, this is no 
prerequisite for its antimicrobial activity (Thevissen et al. 2005) though the 
conformation of short peptides restrained by disulfide bonds could modulate 
their stability in liquid media (Haag et al. 2012; Morehead et al. 1984; van 
Kraaij et al. 2000). Ib-AMP4 can be chemically synthesized, but we have 
chosen biotechnological production as an alternative. If this AMP should be 
used in clinical studies we would need large amounts of the peptides. In this 
case the biotechnological production would be cheaper than chemical 
synthesis. 
We reported the successful production of Ib-AMP4 as a fusion protein in 
Escherichia coli and the Ib-AMP4’s cleavage from the fusion protein, 
purification, and activation.  
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3.3 Results  
3.3.1 Construction of plasmid pET32A-Trx-Ib-AMP4 
The constructed plasmid is shown in Figure 9. The Ib-AMP4 gene was fused 
with a Trx gene to inhibit the antimicrobial activity of Ib-AMP4 during its 
expression. Thus, Ib-AMP4 was expressed as a fusion protein with its 
N-terminal coupled with the C-terminal of Trx. Between them was an rEk 
cleavage site, which allows the tidy excision of Ib-AMP4 from its fusion partner. 
The 6x His-tag between Ib-AMP4 and Trx was used as a purification tag.  
 
 
Figure 9. Design of the expression vector pET32a-Trx-Ib-AMP4. A) The DNA of Ib-AMP4 
was inserted into vector pET32a between Hind III and Kpn I restriction sites. Vector 
pET32a possessed a T7 promoter which could be activated by lactose or IPTG. This 
vector also encoded a lactamase which rendered ampicillin resistance to the transformed 
bacteria as a screening marker. After expression, B) The peptide Ib-AMP4 was fused at 
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the C-terminal of a thioredoxin and between there were a 6X His tag and a rEk cleavage 
site, designed for the purification of Ib-AMP4.  
3.3.2 Fusion expression and purification 
The constructed plasmid pET32A-Trx-Ib-AMP4 was transformed into an 
Escherichia coli BL21 strain for expression. The fusion protein was expressed 
within the cytoplasm mainly in a soluble form after IPTG induction and 
accounted for approximately 20% of the total protein in Escherichia coli cells, 
as shown by the SDS–PAGE results (Figure 10, lane 3). The fusion protein 
yield was approximately 50 mg/l culture. Most of the impurities were removed 
during affinity chromatography. The fusion protein carrying a His-tag with a 
purity of more than 80% was easily retrieved by nickel affinity chromatography 
(Figure 10, lane 6).  
 
Figure 10. Expression and purification of Ib-AMP4. Lane M: size marker; lane 1: total 
protein after cell lysis; lane 2: insoluble protein after lysis; lane 3: soluble protein after lysis; 
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lane 4: impurity washed out from the nickel affinity column; lane 5: fusion protein retrieved 
by nickel affinity chromatography; lane 6: protein after ultrafiltration; lane 7: protein after 
rEk cleavage. The arrow points at the fusion protein. 
3.3.3 rEK cleavage and Ib-AMP4 isolation         
The elution from affinity chromatography was applied to the dialysis against 
the rEK cleavage buffer to adjust the pH and ion concentration. The protein 
solution was used for ultrafiltration (10 kD) (Figure 10, lane 6) after dialysis to 
concentrate the protein sample to 4 mg/ml. We removed an impurity (lower 
than 10 kD molecular weight, which would interfere with the subsequent step 
of Ib-AMP4 isolation. The fusion protein was cleaved into two fragments of 20 
kD and 2.5 kD after the rEk cleavage (Figure 10, lane 7). Ib-AMP4 was 
isolated by applying the cleavage sample to Sephadex G25 to remove the 
fusion partner. A purity of higher than 90% for the peptide fraction was 
eventually reached (Figure 11A), and the final yield was approximately 8 mg 
Ib-AMP4 /l medium. Ib-AMP4 with an ultra purity of higher than 95% was 
obtained by using an extra purification step by HPLC. The MALDI-MS revealed 
the presence of a molecular ion of m/z 2542, which was consistent with the 
Ib-AMP4 theoretical mass (Figure 11B). 
 
 
 
 
45 
A 
 
 
B 
 
 
46 
C 
 
Figure 11. Spectral analysis of Ib-AMP4. A) Purity analysis by HPLC of Ib-AMP4 after 
Sephadex G-25 filtration; B) Mass spectrum of the purified Ib-AMP4; C) Mass spectrum of 
Ib-AMP4 after activation. 
3.3.4 Activation and stability 
Activation of the Ib-AMP4 can be shown by its improved MIC against 
Staphylococcus aureus, the smaller the MIC, the better the activation. As 
shown in Figure 12A, the peptide was hardly active before activation with a 
MIC of about 200 µg/ml, whereas samples stored at 4 °C were relatively stable 
and their activity was persistent until day 20, storage at 37 °C led to a loss of 
activity after 8 d. In addition, Ib-AMP4 also showed a good thermal stability 
(Figure 12B). 
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The disulfide bond failed to form within Escherichia coli cells because of the 
lack of posttranslational modification. Thus, an extra step of activation for 
Ib-AMP4 was required to form two disulfide bridges. The two disulfide bridges 
were formed by either self-oxidization by oxygen or by adding H2O2 at 5 μg/ml 
to the Ib-AMP4 solution. The result shows that self oxidization occurred slowly 
for several days and required a suitable temperature, such as RT. RT was not 
beneficial to the stability of Ib-AMP4. H2O2 application and significantly 
decreased the activation time to less than 24 h. Ib-AMP4 was adjusted to 
400 μg/ml for activation to avoid a disulfide mismatch. A weight loss of 4 Da 
occurred after activation by 5 µg/ml H2O2, as determined by MS (Figure 12C). 
This change in M+ 
 
indicated the formation of two intramolecular disulfide 
bonds.  
A 
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Figure 12. Activation and stability of Ib-AMP4. A) Activation of Ib-AMP4 and its 
bactericidal effect. Three lyophilized samples were dissolved in ddH2O to a final 
concentration of 400 µg/ml, but were processed differently to optimize the condition for 
oxidation: Experiment 1: plus 5 µg/ml H2O2 and 4 °C; Experiment 2: without H2O2 at 
37 °C; Experiment 3: without H2O2
3.4 Discussion 
 at 4 °C. MIC values of three Ib-AMP4 preparations 
were determined against Staphylococcus aureus ATCC 25923. B) Thermal stability of 
Ib-AMP4. The active Ib-AMP4 samples were pretreated at different temperature and then 
tested their antimicrobial activity against B. megaterium. Antimicrobial activity of Ib-AMP4 
was stable after several cycles of thawing-frozen or heat at 59 degree for 1 h, but 100 
degree water bath reduced the antimicrobial efficiency.  
The expression of antimicrobial peptides remains an issue. Their production in 
plant seems very limited because of the poor expression, but they also could 
not be easily expressed in microorganism since they are antimicrobial agents. 
To solve this problem, fusion strategy was commonly adopted for expression 
of exogenous proteins in microorganisms including Escherichia coli and yeast 
(Katoh et al. 2010; Wu et al. 2010), but it always left extra amino acids in short 
peptides after protease cleavage. There were also some other papers 
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introduced the application of intein for expression of peptides without usage of 
protease. However, the cleavage was unpredictable and of poor yield (Diao et 
al. 2007; Hong et al. 2010). In this report, a pET32 plasmid expressing a fusion 
partner of thioredoxin was chosen to express a fusion protein, i.e. Ib-AMP4 
with TRX, and an enterokinase cleavage domain was inserted directly before 
the target peptide. This construct allowed the controlled and sufficient 
cleavage of Ib-AMP4 from its fusion partner thioredoxin without leaving any 
extra amino acid.  
As the figure of expression showed, there is only one band of fusion protein 
after purification which indicates almost no degradation happened. Instability 
of the recombinant protein might be expected, although BL21 is apparently 
deficient in the Ion and ompT proteases and many proteins produced in this 
strain are quite stable. The fusion chaperons function not only as an 
expression helper but also help the stability. The thioredexin partner from 
pET32 plamid is a homologous protein of Escherichia coli and confers 
resistance of the recombinant to inner protease degradation in Escherichia coli 
cells.  
The results suggested that the soluble expression of the exogenous proteins 
should be performed under low temperature (Kiefhaber et al. 1991; Schein 
1989; Xu et al. 2005). Referring to the previous researches, the temperature 
seemed to be the most important parameter influencing the soluble expression. 
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Under different temperatures, the heterogenetic protein could be expressed as 
different conformations, and it has been reported that growth at 37 °C causes 
some proteins to accumulate as inclusion bodies, while incubation at 28 °C 
leads to soluble, active protein . It is possible that the temperature could 
influence the activity of the protein synthases which decide the synthesis rate, 
and, moreover, the synthases with low activity under low temperature allow 
enough time for protein to refold into a correct conformation (Kiefhaber et al. 
1991; Xu et al. 2005).  
The purification steps appeared simple and efficient. The fusion protein easily 
achieved more than 80% purity after nickel affinity chromatography. Only three 
further steps were needed to obtain a purity of more than 90% for Ib-AMP4. 
We used ultrafiltration after nickel affinity chromatography because the elution 
solution consisted of several bands. This procedure was critical in removing 
protein fragments with an MW below 10,000 kD. The activity of Ib-AMP4 was 
firstly very low. We assumed that the weak activity was related to the failure to 
form disulfide bonds (Patel et al. 1998). Hence, Ib-AMP4 could be successfully 
activated by H2O2 after purification. Mass spectral analysis confirmed the 
activation by H2O2
H
 and the formation of two disulfide bonds.  
2O2 is bactericidal and could thus interfere with the antimicrobial test. To 
exclude its effect, H2O2 was used at a maximum of 5 µg/ml for oxidation 
because all tested bacteria were unaffected by this concentration. Moreover, 
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most of the tested MICs of Ib-AMP4 were between 4 and 32 µg/ml. It means 
that the peptide preparation containing 5 µg/ml H2O2 has to be diluted for more 
than 10 times and the effect of H2O2 
In conclusion, Ib-AMP4 was successfully expressed in Escherichia coli cells as 
a fusion protein, and a simple approach to activate the peptide after enzymatic 
cleavage and purification could be established. This method might be useful 
for other AMPs with multiple disulfide bridges. 
would become negligible. 
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 Chapter 4. Ib-AMP4 could selectively target bacteria but 
is sensitive to cations†
4.1 Abstract 
  
As important constituents of the innate immune system, AMPs are active 
against infectious microorganisms, such as bacteria, and can distinguish host 
cells from invading pathogens. To evaluate the potential of Ib-AMP4 as a 
clinical medicine, its antimicrobial activity was studied. Ib-AMP4 was applied 
alone and in combination with current antimicrobial agents to human 
pathogens, including MDR strains. Ib-AMP4 cytotoxicity and hemolysis activity 
were investigated. The inhibitory effect of cations on the Ib-AMP4 antimicrobial 
activity was also explored. 
Antimicrobial assays showed that most of the tested MICs were within the 
range of 2 mM to 20 mM, and Ib-AMP4’s antimicrobial activity was 
independent of resistance to current antibiotics. Ib-AMP4 can efficiently target 
both susceptible and resistant bacteria, including MRSA and ESBL-
                                            
† This chapter has been published as: “Fan, X., Reichling, J., Wink, M., Antibacterial activity of the 
recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other 
antimicrobial agents against drug resistant bacteria, Pharmazie, 68 (2013) 628-630. 
producing 
E. coli. Given the unique antimicrobial mechanism of AMPs, the combination of 
Ib-AMP4 and other antimicrobial agents is a promising solution to the drug 
resistance problem. A genuine synergistic effect was achieved when Ib-AMP4 
” 
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was used in combination with the plant monoterpene thymol or kanamycin 
against drug-resistant Klebsiella pneumoniae (KPC) ATCC700603, or with the 
antibiotics vancomycin or oxacillin against Enterococcus faecalis (VRE) 
ATCC51299. 
Time kill experiments showed that Ib-AMP4 showed bactericidal activity within 
10 min after application. Hemolysis and cytotoxicity assays indicated the 
selectivity of Ib-AMP4 toward the bacteria, which is an important prerequisite 
for clinical applications. However, Ib-AMP4 efficiency was generally inhibited 
by cations, especially divalent cations.  
Recombinant lb-AMP4 is an interesting and powerful AMP with bactericidal 
properties against Gram-positive and Gram-negative bacteria, including MDR 
pathogens. Ib-AMP4 is an interesting candidate for clinical studies involving 
patients with septicemia or for coating clinical devices, such as catheters.  
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4.2 Introduction 
Until modern times most human deaths were caused by microbial infections. 
The discovery of antibiotics, beginning with that of penicillin in 1928, has 
revolutionized medicine, but many pathogens have since become resistant to 
antibiotics due to drug abuse and improper drug usage. 25,000 people in the 
European Union are presently dying each year from being seriously infected 
by resistant bacteria pathogens, mostly acquired in health-care settings (Carlet 
et al. 2012; Spellberg et al. 2004). Techniques of drug development today are 
much more powerful than in earlier decades, but most antimicrobial candidates 
being developed are variations on previous antibiotics or similar to them so 
they are likely to provoke new resistance, since similar targets are involved 
(Carlet et al. 2012; Spellberg et al. 2004). Drug R&D has plummeted, due to a 
shortage of research investment and innovation, while resistance to drugs 
keeps on developing faster and faster, threatening to lead us back into the 
pre-antibiotic era, when a mere scratch could be fatal (Carlet et al. 2012; 
Spellberg et al. 2004). 
Antimicrobial peptides (AMPs), produced by fungi, plants and animals, have 
received a lot of attention in having the potential to contribute solving the drug 
resistance problem. Unlike traditional antibiotics, AMPs seem to function like 
surfactants due to their amphiphilic character (Nan et al. 2011) but can 
The discovery of antibiotic with novel antimicrobial 
mechanism really becomes a matter of emergency. 
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selectively target bacterial membranes and make them leaky (Li et al. 2012; 
Shenkarev et al. 2011; Tang and Hong 2009). AMPs can intercalate 
biomembranes and can disrupt them as a consequence, whereas traditional 
antibiotics target mainly bacterial metabolism or cell walls. This difference 
ensures a low cross-resistance (Reddy et al. 2009) and a good potential for 
synergy between AMPs and classical antibiotics (Aleinein et al. 2014; Nguyen 
et al. 2011).  
The targeting of biomembranes by AMPs is thought to be achieved in three 
steps. At first, the peptides are electrostatically attracted by the negatively 
charged compounds from both the cell wall and cell membrane, i.e. LPS, PS 
and PG, which concentrate them on the bacterial surface (Lee et al. 2011; Nan 
et al. 2011). Next, the peptides approach the membrane and, due to their 
amphiphilic character, insert themselves into the lipid bilayers. Finally, leak 
channels are formed in bacterial membranes, which may disable cellular 
respiration and allows essential metabolites to leak out of the cells (Nguyen et 
al. 2011). Why some peptides selectively target Gram positive or Gram 
negative bacteria is still uncertain (Rahnamaeian 2011).  
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4.3 Results 
4.3.1 Antimicrobial assay using susceptible strains 
All susceptible species were obtained from ATCC. These bacteria are 
commonly referred to as standard bacteria because they have not developed 
any resistance to current antibiotics.  
The results show that Ib-AMP4 is a broad-spectrum antimicrobial agent. It 
exhibits broad activity against both Gram-positive and Gram-negative bacteria 
(Table 4) with MICs between 1 and 20 µg/ml in sensitive bacteria. Some 
bacteria, such as E. faecalis, Streptococcus agalactiae, S. oralis, S. 
epidermidis, K. oxytoca, and Pseudomonas aeruginosa, showed low 
sensitivity (i.e., MIC values between 40 and 160 µg/ml). These differences may 
be due to cell wall and biomembrane composition (de la Fuente-Nunez et al. 
2012). 
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Table 4. MICs for recombinant Ib-AMP4 against Gram-positive and Gram-negative 
bacteria. 
   Bacterial Species ATCC No.     MIC (μg/ml) 
 
Gram positive bacteria      
Bacillus megaterium 14581 0.63~1.25  
 Bacillus subtilis 6051 1.25~2.5  
 Micrococcus luteus 7468 2.5~5  
 Streptococcus agalactiae 27956 80~160  
 Enterococcus faecalis 29212 20~40  
 Staphylococcus oralis 35037 40~80  
 Staphylococcus epidermidis  14990 40~80  
 Staphylococcus aureus 29213 5~10  
  25923 5~10  
 Staphyloccus saprophyticus 15305 1.25~2.5  
 Streptococcus pneumoniae 49619 10~20  
 Streptococcus pyogenes  12344 5~10 
 
Enterococcus casseliflavus 700327 2.5~5 
Enterococcus faecalis 51299 40~80  
Gram negative bacteria   
 
Klebsiella oxytoca 700324 20~40  
Klebsiella pneumoniae 700603 60~120  
 Escherichia coli 25922 5~10  
  35150 4~8  
 Pseudomonas aeruginosa 27853 80~160  
4.3.2 Antimicrobial assay over clinical isolates 
Most of these clinical isolates were drug resistant, but no clear differences 
were observed between susceptible and resistant strains from the same 
species. The results of antimicrobial assays are summarized in Table 5. 
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Ib-AMP4 exhibited a broad activity spectrum over both Gram-positive and 
Gram-negative bacteria. Some bacteria, such as E. faecium, E. cloacae, E. 
aerogenes, E. coli, S. haemolyticus, and Staphylococcus aureus, were 
susceptible to Ib-AMP4 with MICs between 2 and 16 µg/ml. The other bacteria 
were less susceptible and showed susceptibility only with MICs between 32 
and 128 µg/ml. Acinetobacter calcoaceticus, P. aeruginosa, and Citrobacter 
freundii were resistant to Ib-AMP4.  
Table 5. Survey of Ib-AMP4 antibacterial activity (MIC values). 
Bacteria No.* MIC (μg/ml) 
Gram-negative bacteria   
Acinetobacter calcoaceticus CI 110125202* >128 
Proteus vulgaris CI 110125206 32~64 
Proteus mirabilis CI 110224201 32~64 
 CI 110315208 64~128 
Enterobacter cloacae CI 110212223 4~8 
 CI 100930201 4~8 
Enterobacter aerogenes CI 110307204 2~4 
Serratia marcescens CI 110126205 8~16 
 CI 110127207 8~16 
Pseudomonas stutzeri CI 110207202 64~128 
Pseudomonas aeruginosa CI 110303204 >128 
Klebsiella oxytoca CI 110314209 32~64 
Klebsiella aerogenes CI 110307204 16~32 
Citrobacter freundii CI 110208201 >128 
Escherichia coli ATCC 25922 4~8 
 CI 110316207** 4~8 
 CI 110215211** 4~8 
 CI 110215212** 4~8 
Gram-positive bacteria   
Enterococcus faecium CI 110125213 2~4 
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 CI 110201208 4~8 
 CI 110211212 2~4 
Streptococcus pneumoniae CI 11021131 16~32 
Staphylococcus haemolyticus CI110127208 8~16 
Staphylococcus epidermidis CI 110126211 16~32 
Staphylococcus aureus ATCC 29213 4~8 
 CI 110126209 4~8 *** 
 CI 110126210 4~8 *** 
 CI 110302214 8~16 *** 
* CI clinical isolates; ATCC American type culture collection; ** ESBL-producing 
Escherichia coli was resistant to ampicillin, cefazolin, ceftazidime, cefepime, gentamicin, 
and cotrimoxazole; *** MRSA was resistant to penicillin, oxacillin, and cefotetan.  
4.3.3 Ib-AMP4 combined with antimicrobial agents 
The combination test indicated a slight additive effect between Ib-AMP4 and 
the antimicrobial agents (Table 6,7). Ib-AMP4 application reduced the use of 
these antimicrobial agents, and notable synergistic effects were achieved for 
Ib-AMP4 combined with oxacillin against MRSA and for Ib-AMP4 combined 
with vancomycin against VRE.  
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Table 6. Combination of Ib-AMP4 with other antimicrobial agents by the checkerboard 
method. 
 K. pneumoniae   S. aureus   E. faecalis  
Combination*  MIC (µg/ml)1  FIC
 
2 Combination* MIC (µg/ml)1  FIC
 
2 Combination*  MIC (µg/ml)1   FIC
 
2 
AgNO3  (8.75)  AgNO3   (8.0)  AgNO3  (45）  
1.75 µg/ml + P 106.67 1.09 2 µg/ml + P 11.85 0.72 9 µg/ml + P 71.11 1.06 
2.63 µg/ml + P 71.11 0.89 3 µg/ml + P 7.9 0.69 18 µg/ml + P 71.11 1.22 
3.5 µg/ml + P 47.41 0.79 4 µg/ml + P 7.9 0.82 27 µg/ml + P 4.16 0.55 
4.38 µg/ml + P 31.6 0.76 5 µg/ml + P 7.9 0.94 36 µg/ml + P 1.23 0.68 
Thymol (750)   Thymol (250)   Thymol (625)   
187.5 µg/ml + P 31.6 0.51 25 µg/ml + P 25 1.1 62.5 µg/ml + P 47.41 0.69 
281.25 µg/ml + P 14.05 0.49 50 µg/ml + P 20 1 187.5 µg/ml + P 31.6 0.7 
375µg/ml + P 14.05 0.62 125 µg/ml + P 8.446 0.84 250 µg/ml + P 14.05 0.58 
468.75 µg/ml + P 9.36 0.7 150 µg/ml + P 6.33 0.85 312.5 µg/ml + P 6.24 0.58 
EDTA (745)   EDTA (60)   Vancomycin (7.5)   
93.11 µg/ml + P 47.41 0.52 7.45 µg/ml + P 25 1.13 0.75 µg/ml + P 80 1.1 
186.22 µg/ml + P 47.41 0.65 14.9 µg/ml + P 25 1.25 1.5 µg/ml + P 47.41 0.79 
279.33 µg/ml + P 47.41 0.77 22.35 µg/ml + P 25 1.38 2.25 µg/ml + P 14.05 0.48 
372.44 µg/ml + P 31.6 0.76 52.14 µg/ml + P 7.9 1.19 3 µg/ml + P 9.36 0.52 
Vancomycin (120)   Oxicillin (50)   Oxicillin (32) 32  
12 µg/ml + P 120 1.1 5 µg/ml + P 11.25 0.55 3.2 µg/ml + P 44.8 0.66 
24 µg/ml + P 120 1.2 10 µg/ml + P 8.44 0.54 6.4 µg/ml + P 25.6 0.52 
36 µg/ml + P 120 1.3 15 µg/ml + P 6.33 0.55 9.6 µg/ml + P 19.2 0.54 
48 µg/ml + P 120 1.4 20 µg/ml + P 4.75 0.59 12.8 µg/ml + P 2.4 0.43 
* Checkerboard method was used for the combination test. Different combinations were 
obtained by testing the MICs of Ib-AMP4 in media with serial constant concentrations of 
indicated agents ranging from 0.1x MIC to 1x MIC. Values in brackets represent the MICs 
of indicated agents against respective bacteria. P represents the Ib-AMP4 peptide. 
1 The values are the detected MICs of Ib-AMP4 in indicated combinations 
2 FIC=FICA + FICB  (FICA=MIC (A in combination with B)/MIC (A alone); FICB=MIC (B 
in combination with A)/MIC (B alone) ). FIC >2.0 indicate antagonistic effects, 0.5<FIC< 
2.0 indicate additive effects, and FIC<0.5 indicate synergistic effects (shown in Italic).  
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Table 7. Ib-AMP4 recovered the susceptibility of MDR strains to antimicrobial agents. 
 K. pneumoniae   S. aureus   E. faecalis  
Combination*  MIC (µg/ml)1  FIC
 
2 Combination*   MIC (µg/ml)1  FIC
 
2 Combination*   MIC (µg/ml)1   FIC
 
2 
Sanguinarine (46.875) Sanguinarine (91.465)  Sanguinarine (7.812) 
0.2X Ib-AMP4 46.875  1.200  0.2X Ib-AMP4 1.099  0.950  0.2X 
 
5.859  0.950  
0.4X Ib-AMP4 35.156  1.150  0.4X Ib-AMP4 1.099  1.150  0.4X 
 
3.296  0.822  
0.6X Ib-AMP4 10.417  0.822  0.6X Ib-AMP4 0.824  1.163  0.6X 
 
1.854  0.837  
Quonolone (264)  Quonolone (16)  Quonolone (132)  
0.2X Ib-AMP4 264  1.200  0.2X Ib-AMP4 16  1.200  0.2X 
 
74  0.763  
0.4X Ib-AMP4 198  1.150  0.4X Ib-AMP4 12  1.150  0.4X 
 
42  0.716  
0.6X Ib-AMP4 148  1.163  0.6X Ib-AMP4 12  1.350  0.6X 
 
10  0.675  
Kanamycin 
 
  Kanamycin (4)   Kanamycin (750) 
0.2X Ib-AMP4 8  0.378  0.2X Ib-AMP4 4  1.200  0.2X 
 
750  1.200  
0.4X Ib-AMP4 5  0.500  0.4X Ib-AMP4 4  1.400  0.4X 
 
422  0.963  
0.6X Ib-AMP4 3  0.656  0.6X Ib-AMP4 3  1.350  0.6X 
 
178  0.837  
Berberine (250)  Berberine (16)  Berberine ()(250)  
0.2X Ib-AMP4 250  1.200  0.2X Ib-AMP4 16  1.200  0.2X 
 
250  1.200  
0.4X Ib-AMP4 250  1.400  0.4X Ib-AMP4 16  1.400  0.4X 
 
250  1.400  
0.6X Ib-AMP4 125  1.100  0.6X Ib-AMP4 4  0.850  0.6X 
 
125  1.100  
* 0.2X, 0.4X, 0.6X Ib-AMP4 indicate 0.2X, 0.4X or 0.6X MIC of Ib-AMP4 to respective 
bacterium was used in the combination. The MIC values were the tested MIC of indicated 
compounds in combination with Ib-AMP4. 
1 The values are the detected MICs of indicated agents combined with a given 
concentration of Ib-AMP4  
2 FIC=FICA + FICB  (FICA=MIC (A in combination with B)/MIC (A alone); FICB=MIC (B 
in combination with A)/MIC (B alone) ). FIC >2.0 indicate antagonistic effects, 0.5<FIC< 
2.0 indicate additive effects, and FIC<0.5 indicate synergistic effects (shown in Italic). 
4.3.4 Time-killing effect of Ib-AMP4  
The bactericidal results revealed that 99% of Staphylococcus aureus cells 
were killed within 10 min after treatment with 20 µg/ml Ib-AMP4 (Figure 13). 
Compared with traditional antibiotics, Ib-AMP4 failed to kill bacterial cells by 
interfering with metabolism. Compared with vancomycin, Ib-AMP4 ruptured 
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the lipid membrane and caused an acute bactericidal effect, which prevented 
cells from developing resistance over time.  
A 
     
 
B 
 
Figure 13. Rapid bactericidal effect of Ib-AMP4. A) Time killing curve of Ib-AMP4 against 
Staphylococcus aureus ATCC29213. Error bars indicate SD values. B) Comparison of 
bactericidal effects between Ib-AMP4 and vancomycin. Compared with Ib-AMP4, 
vancomycin targeted the cell wall, which caused a much slower bactericidal effect and 
allowed bacterial cells to develop resistance by metabolic alteration. 
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4.3.5 Anticancer effect and hemolysis activity  
A potential membrane-disrupting effect of Ib-AMP4 on sheep erythrocytes and 
A459 cancer cells was investigated. H2O2
The Ib-AMP4 cytotoxicity was limited. The peptide neither caused hemolysis 
nor inhibited cell proliferation (<2%) at concentrations lower than 100 μg/ml. 
Ib-AMP4 at 200 μg/ml caused 15% hemolysis of red blood cells and 8% 
inhibition of cell proliferation.  
 was introduced during the activation 
step. Thus, the maximal concentration of Ib-AMP4 applied to cancer cells was 
200 mg/ml or lower. The antimicrobial assay results show that the MICs for 
most of these test bacteria were below 100 mg/ml. These concentrations used 
on cancer cells provided a good reference for the acute cytotoxicity of Ib-AMP4 
in vivo.  
4.3.6  Cations affect AMPs 
The cation effect on Ib-AMP4 antimicrobial activity was measured by 
supplementing the medium with extra monovalent cations (i.e., sodium or 
potassium) or divalent cations (i.e., calcium or magnesium). The MICs of 
Ib-AMP4 against B. megaterium in MH medium supplemented with different 
concentrations of salt were tested. The MIC of Ib-AMP4 against B. megaterium 
was 6.5 µg/ml in salt-free medium. Both monovalent and divalent cations 
prohibited Ib-AMP4 antimicrobial activity, but divalent cations were more 
effective than monovalent cations. The MIC obtained by adding 25 mM 
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calcium/magnesium was double that obtained by adding 400 mM 
sodium/potassium.  
To understand the universal effect of cations on antimicrobial activity of 
Ib-AMP4, we also tested the MICs of Ib-AMP4 against 17 bacterial species in 
medium supplemented with 25 mM CaCl2. Ib-AMP4 activity was inhibited by 
CaCl2 in all tested species. The MICs increased to at least twice as high as 
those from the CaCl2
Table 8. MICs for recombinant Ib-AMP4 against gram positive and gram negative bacteria 
-free medium. The MIC increased by more than 10 times 
for some species, such as E. coli.  
   Bacteria Species ATCC No. 
MIC 
Calcium-free 
medium 
Calcium-loaded 
medium 
 
Gram-positive bacteria     
Bacillus megaterium 14581 1.25  10 
 Bacillus subtilis 6051 2.5 10 
 Micrococcus luteus 7468 5 20 
 Streptococcus agalactiae 27956 160 160 
 Enterococcus faecalis 29212 40 80 
 Staphylococcus oralis 35037 80 >200 
 Staphylococcus epidermidis  14990 80 >160 
 Staphylococcus aureus 29213 10 50 
 
 25923 10 40 
Streptococcus pneumoniae 49619 20 40 
 Streptococcus pyogenes  12344 10 40 
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 Enterococcus casseliflavus 700327 5  20 
 Gram-negative bacteria    
 
Klebsiella oxytoca 700324 40  >160 
Klebsiella pneumoniae 700603 120 160 
Escherichia coli 25922 10 160 
 
 35150 8  160) 
Pseudomonas aeruginosa 27853 160  >160 
A 
 
B 
 
Figure 14. Cations affecting Ib-AMP4 antimicrobial activity. A) Inhibitory effect of 
monovalent sodium and potassium. B) Inhibitory effect of divalent calcium and 
magnesium.  
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4.4 Discussion 
Ib-AMP4 was discovered as a highly effective agent against Gram positive 
bacteria but with much lower potential against Gram negative species such as 
Escherichia coli (Tailor et al. 1997). This result differs from our findings, as in 
our experiments Ib-AMP4 affected both gram-positive and gram-negative 
bacteria (Table 6,7). Although we tried the same medium and the same 
bacteria we could not confirm the original results [15].  
AMPs sufficiently target either Gram-positive or Gram-negative bacteria in 
most cases (Hammami et al. 2009). Ib-AMP4 was effective against both 
Gram-positive and Gram-negative bacteria. At the moment, MRSA and 
ESBL-producing Escherichia coli are the two most widely prevalent drug 
resistant species in clinical settings (Table 1). Ib-AMP4 showed a promising 
effect on these two species. Similar MIC values were observed between drug 
resistant and susceptible strains, thereby indicating that Ib-AMP4 antibacterial 
activity was independent of the resistance of the species to other drugs. The 
Ib-AMP4 showed a mode of action that was different from that of traditional 
antibiotics, which showed no effect on drug-resistant pathogens. AMPs target 
and destroy the cell membrane. However, human cells also have membranes. 
Thus, many compounds that target cell membranes are not sufficiently 
selective for use in a clinical setting. Compared with eukaryotic cells, bacteria 
have more acidic phospholipids in their outer membranes and lack cholesterol. 
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Positively charged AMPs are prone to interacting with negatively charged 
substances and are selective toward bacteria (Epand and Epand 2011). 
Furthermore, the respiratory chain in bacteria is located in the plasma 
membrane, which has to be intact for the organism’s function; AMPs that 
induce leakiness in cell membranes are ideal antibiotics because they disturb 
cellular respiration (Haddock and Jones 1977). 
We tested the potential synergy of Ib-AMP4 combinations with established 
antimicrobial agents to further understand Ib-AMP4’s antimicrobial potential. 
Silver has been used as an antibacterial agent for centuries before the 
discovery of the first modern antibiotics, such as penicillin. Silver could kill 
bacteria either indirectly by producing highly reactive oxygen species or 
directly by inactivating proteins (Davies and Etris 1997). Plant monoterpene 
thymol is another compound with a long history; thymol usage dates back to 
ancient Egypt when this compound was used to preserve mummies. Thymol 
interacts with bacterial membranes. Being a phenolic compound, thymol 
dissociates into a phenolate ion under physiological conditions; thus, thymol 
can interact with proteins (Rosenkranz and Wink 2008; Trombetta et al. 2005). 
Sanguinarine and berberine are quaternary ammonium salts isolated from 
plants and used as traditional medicines against infections. Membrane ion 
channels are predicted as their potential targets. EDTA causes instability in the 
cell membrane by chelating divalent cations. EDTA has already been used 
68 
with traditional antibiotics to overcome drug resistance (Aoki et al. 2010; 
Berges et al. 2007; Martin-Visscher et al. 2011; Raad et al. 2007). Vancomycin 
and oxacillin are cell wall inhibitors that block the crosslinking of the 
peptidoglycan net. Quinolone exerts antibacterial activity by preventing 
bacterial DNA from unwinding and duplicating. Kanamycin inhibits bacterial 
infection by interrupting bacterial protein translation. A promising combination 
of Ib-AMP4 with these antimicrobial agents is expected because their modes 
of action are different.  
Some reports showed that AMPs could neutralize endotoxins such as LPS. 
Such findings are important as regards the outbreak of EHEC in Germany in 
2011, which illustrated the fatal role of endotoxins produced by pathogens 
sensitive to antibiotics (Li et al. 2004). AMPs may be usefully applied under 
such conditions. If applied against acute septicemia antibiotics have the 
drawback of being slow to kill pathogens, letting them produce more 
life-threatening endo- and exotoxins (Mikkelsen and Gaieski 2011; Souza and 
Yuen 2012). In view of the rapid bactericidal activity and endotoxin binding 
ability of AMPs, AMP treatment could stop the production of endo- and 
exotoxins and neutralize them. Studies with animals suffering from septicemia 
are now needed, to find out whether or not Ib-AMP4 also works in vivo. If it 
does, it may be used in humans. Another application could be to coat medical 
devices such as catheter left in the human body for extended periods of time. 
69 
Such medical devices sometimes become infected and cause severe bacterial 
infections in patients. Furthermore, research is needed for adequate 
formulations which allow a stable and safe application. 
Ions are physically essential for all living organisms and are involved in many 
vital cellular events, such as enzymatic catalysis and maintenance of 
transmembrane potential. Unlike mammalian cells where calcium is used to 
maintain the transmembrane potential, bacterial cells require a sufficient 
supply of cations, especially Ca2+ and Mg2+
Ib-AMP4 was successfully purified from Escherichia coli cells. This peptide 
showed promising antimicrobial activity. Ib-AMP4 was sensitive to cations, but 
Ib-AMP4 killed most of the clinical isolates with MICs between 2 and 32 µg/ml. 
The peptide showed neither hemolysis nor cytotoxicity within this MIC range, 
which is the condition required for the clinical application of Ib-AMP4. 
Combined with traditional antimicrobial agents, Ib-AMP4 recovered the 
susceptibility of drug-resistant strains. Ib-AMP4’s promising antimicrobial 
 for growth and metabolism. In the 
presence of a chelator for divalent cations, a bacterium would lose the original 
shape of its outer membrane. Mammalian cells use cations to regulate 
transmembrane channels for transport. Similarly, calcium can help in the 
construction of bacterial outer membrane, thereby affecting the permeability at 
the outer membrane and cell wall.  
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effects, particularly on MRSA and ESBL-producing E. coli, indicated the 
significant potential of using Ib-AMP4 to solve drug resistance problems.  
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Chapter 5. Interaction between Ib-AMP4 with LPS and 
calcium effects 
5.1 Abstract  
Negatively charged LPS is an important component of the cell wall of 
Gram-negative bacteria and is closely related to AMP targeting. LPS can 
easily be purified and is an important model for studying the roles of cell walls 
and cell membranes in AMP targeting. Interaction between Ib-AMP4 with LPS 
and the Ca2+ effect were elucidated by monolayer experiments and QCM-D. 
Ib-AMP4 can intercalate into LPS-Re, and Ca2+ can potentially modulate such 
intercalation. LPS absorbed calcium ions at the headgroups and aligned into 
an orderly and compact matrix in the presence Ca2+. Calcium ions were used 
by the cell wall to electrically repel Ib-AMP4 and thus to reduce the cell wall’s 
permeability to Ib-AMP4.   
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5.2 Introduction  
The initial interaction between AMPs and their target microbes occurs through 
electrostatic attraction. The AMP charge is highly associated with antimicrobial 
activity (Bessalle et al. 1992; Lee et al. 2013; Matsuzaki et al. 1997; Sato and 
Feix 2006; Yeaman and Yount 2003). AMPs from different species are also 
conserved by a highly positive charge (Gueguen et al. 2006; Seshadri 
Sundararajan et al. 2012; Wang et al. 2009).  
The bacterial cell wall is located beyond the plasma membrane and protects 
bacterial cells as a first line of defense. All substances that enter or approach 
the bacterial cell membrane have to pass through the cell wall. Unlike the 
membrane channel that is only open for selected substances, the cell wall 
does not show any selectivity, but is related to drug resistance. A predicted 
mechanism underlying this phenomenon is that the bacterial cell’s drug 
resistance can be promoted by modulating the cell wall’s permeability.  
In Gram-positve bacteria, the cell wall consists of multiple layers of 
peptidoglycan interspersed with teichoic acids which are unique to 
Gram-positive cell walls. Different from Gram-positive bacteria, the cell wall of 
Gram-negative bacteria is much complicated. Beyond the peptidoglycan layer, 
there is an extra layer of lipid membrane termed outer membrane for 
Gram-negative bacteria. This outer membrane is linked to the inner 
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peptidoglycan by lipoprotein and is anchored with lipopolysaccharide (LPS) at 
the outer leaflet. 
The bacterial cell wall contains many negatively charged components that are 
highly related to the effective targeting of AMPs toward the cell membrane. 
These components can attract highly positively charged AMPs. These AMPs 
aggregate on the cell surface before inserting into the membrane. Several 
findings suggest that LPS induces AMP targeting. However, AMPs show 
irregularity in terms of their preferred target. Some AMPs can only efficiently 
target Gram-positive strains, whereas others can only target Gram-negative 
strains. The source of this bias remains unknown. The possible enhancers 
during AMP targeting are assumed to be charged components from the cell 
wall, charged phospholipids from the amphiphilic membrane, and negative 
transmembrane potential.  
A Langmuir film is a single layer of insoluble molecules fabricated at the 
gas–liquid or liquid–liquid interface. This technology has been widely applied in 
the study of amphiphilic molecules and their interaction with other substances. 
The surface pressure area isotherm is the most important indicator of 
monolayer properties. The surface pressure area isotherm is obtained by 
measuring the surface pressure as a function of the water surface area 
available for each monolayer molecule upon compression. This isotherm is 
used to predict how molecules pack together and also provides information 
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about the internal force between molecules and compressibility of the 
monolayer.  
 As we showed in the antimicrobial test, Gram-negative bacteria showed 
relative strong resistance to Ib-AMP4 in calcium-loaded medium. To 
investigate the role of cell wall especially the Gram-negative bacteria cell wall 
and its interaction with calcium ions during Ib-AMP4 targeting, LPS, the 
Gram-negative cell wall special component, was employed to construct model 
system for study. 
5.3 Result 
5.3.1 LPS isotherm 
In the π-A isotherms for LPS-Re, we observed the effect of calcium ions on 
condensation in the following data: (i) the onset of pressure increase appeared 
at the lower molecular area and (ii) the surface pressure was always lower 
than that in the calcium-free subphase in the same molecular area. These 
findings indicated that calcium affects the intermolecular interactions between 
LPS molecules when the headgroups were compact (Jeworrek et al. 2011).  
 
In the surface potential-molecular area (P-A) isotherm, the surface potential on 
the calcium-loaded buffer was high. This finding indicates the incorporation of 
calcium ions into the headgroup region of LPS (Hagge et al. 2006). Given that 
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calcium has two positive charges, it can increase the effective molecular 
moment and affected the following: (i) the dipole moment of the polar 
headgroup and (ii) the tilt angle of the hydrocarbon chains. The effect of 
calcium on the effective molecular moment directed to the subphase surface 
was qualitatively observed using the Helmholtz equation at a constant 
molecular area as an assumption (Garcia-Verdugo et al. 2007). 
The Helmhotz equation is as follows: 
where the actual moment of the isolated molecule is ε and is aligned 
at some angle θ to the subphase normal. A is the area occupied by 
each molecule and ε0 is the permittivity of free space. 
 
A  
 
B 
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Figure 15. Isotherms for the LPS-Re monolayer in calcium-loaded and -free buffers. A) 
π-A isotherms for LPS-Re; B) P-A isotherms for LPS-Re.  
5.3.2 Ib-AMP4 intercalation increases the LPS-Re monolayer 
surface pressure 
To compare the insertion of Ib-AMP4 at different surface pressures and in 
different buffers, the monolayer was compressed to a target pressure of 10, 17, 
or 25 mN/m in calcium-free buffer, or 17 mN/m in calcium-loaded buffer 
separately. The Ib-AMP4 was injected after compression. The final Ib-AMP4 
concentration was approximately 2 mM. The surface pressure of the LPS-Re 
monolayer increased after Ib-AMP4 injection. The pressure increase caused 
by Ib-AMP4 injection was negatively correlated with the surface pressure on 
the location where the drug was injected. Calcium prohibited the Ib-AMP4 
intercalation in the calcium-loaded buffer at the same molecular area.  
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Figure 16. Ib-AMP4 intercalation increasing the surface pressure. The molecular area at 
17 mN/m in the calcium-loaded buffer is equal to that at 25 mN/m in the calcium-free 
buffer. The pressure increase caused by Ib-AMP4 under different pressure and buffer 
treatments is plotted over time.  
5.3.3 Study of Ib-AMP4 interaction with the LPS-Re vesicle by 
QCM-D 
The unique fundamental frequency of ~5 MHz for a clean quartz crystal was 
recorded by the system before the LPS-Re was coated. After the injection of 
LPS-RE vesicles, the LPS-Re mass was continuously absorbed onto the 
surface, thereby resulting in a decrease in frequency, which finally became 
stable at -90 Hz below the fundamental frequency. The dissipation continued 
to increase, thereby indicating an increase in viscosity in the quartz surface. A 
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90 Hz frequency shift implied that the attached materials were probably intact 
vesicles. 
An immediate mass loss amounting to -60 Hz was observed after applying 
Ib-AMP4 at 10 μg/ml. The LPS-Re vesicle/micelle was broken, and the major 
mass was removed from the quartz.  
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Figure 17. Study of Ib-AMP4 interaction with LPS-Re vesicles by QCM-D. The arrow 
indicates where the Ib-AMP4 was injected. The Ib-AMP4 injection disrupted the LPS-Re 
vesicles and removed most of the materials. 
  
5.4 Discussion 
Injecting Ib-AMP4 underneath an LPS-Re monolayer caused an instant 
adsorption at the monolayer interface, which showed a rapid interaction 
between these two opposite charged compounds. The peptide rupturing LPS 
vesicles at 10 μg/ml by QCM-D indicated affinity for Ib-AMP4 to the target on 
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LPS. The liposome disruption started with the peptide binding/insertion. These 
conditions suggest that the LPS layer located on the cell wall surface was 
electrically attractive and permeable to AMPs.  
In the presence of Ca2+, Ib-AMP4 absorption was dramatically reduced. The 
isotherm profile of LPS-Re was significantly modified by applying Ca2+ to the 
monolayer. The LPS-Re matrix became ordered and compact. This is in 
consistence with previous reports that cations were condensed at the LPS 
monolayer interface. The addition of Ca2+ dramatically resulted into a full 
replacement of K+ from the interface (Abuillan et al. 2013; Oliveira et al. 2010). 
Therefore, Ca2+ built up an electrical defense before the entrance of the LPS 
monolayer. Peptide binding/penetration started with cation displacement. 
Replacing Ca2+ with a peptide rather than Na+/K+ was clearly difficult.  
Ca2+ was unfavorable for Ib-AMP4 antimicrobial activities in all tested species 
during the antimicrobial assay; among these species, Gram-negative species 
showed strong resistance in the presence of Ca2+
 
 (Fan et al. 2013). This might 
be considered in consistent with the result that calcium ions reduce the LPS 
permeability to Ib-AMP4 at the cell envelope and prevent Ib-AMP4 from 
approaching the target membrane by electrical repulsion. 
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Chapter 6. Interaction between Ib-AMP4 with lipid 
membrane 
6.1 Abstract 
Membrane breakage was the unique mechanism by which AMPs exert rapid 
bactericidal activity. A series of molecular events occurred in turn and finally 
resulted in the death of bacterial cells. QCM-D and CD measurements 
indicated that the initial binding of Ib-AMP4 with the membrane started at a 
critical concentration where Ib-AMP4 underwent a conformation change and 
adopted a special β-sheet form to insert into the liposome. Upon Ib-AMP4 
insertion, the swollen liposome was not disassembled, as shown by the DLS 
measurement. Ib-AMP4 insertion induced leakiness and wrinkling of the 
liposome on the membrane surface, as shown by QCM-D. The leakage 
continued while a self-promoting insertion of Ib-AMP4 occurred. The intensive 
leakage finally eased after approximately 20 min.  
The periodic leakage indicated the formation of transient pores across the 
liposome lipid bilayer, which probably occurred by a mechanism similar to that 
described for the sinking-raft model because Ib-AMP4 has a large hydrophilic 
headgroup coupled to a short and small hydrophobic tail. Surface pressure, 
line tension, and curvature strain were probably involved during the pore 
formation and resealing. Previous studies on DOPC single and DOPC/DOPG 
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binary monolayer in calcium-loaded and -free buffers implied that the charge 
property of lipid and cation species in the buffer affected Ib-AMP4 insertion, 
and such effect was independent from that of surface pressure. Cholesterol 
also prohibited Ib-AMP4-induced calcein leakage by changing the membrane 
compressibility and altering the membrane curvature. Furthermore, cations 
prevented Ib-AMP4 insertion by interrupting the conformational change of 
Ib-AMP4 during the insertion stage. 
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6.2 Introduction  
Electrostatic forces exist in a long distance range, and interactions between 
lysine or arginine with phosphate groups in lipid bilayers are particularly strong; 
thus, negatively charged components from both the cell wall and membrane 
promote a mutual and vigorous attraction to highly charged cationic AMPs 
(Mavri and Vogel 1996). The initial interaction between AMPs with their target 
microbes is probably driven by electrostatic attraction. This view is also 
supported by the fact that AMPs from different species showed conserved 
highly positive charges (Gueguen et al. 2006; Seshadri Sundararajan et al. 
2012; Wang et al. 2009). 
The events that followed the initial binding comprised the transition stage, 
during which AMPs changed their binding affinity toward the membrane by 
altering their geometric conformation; a self-promoting association or 
multimerization of AMPs occurred, and AMPs were oriented perpendicular to 
the membrane (Huang 2000; Prado Montes de Oca 2013; Yeaman and Yount 
2003). The membrane finally developed a transmembrane deficiency that 
could either be a hole or a channel. Different speculations have been 
presented for this stage, including the barrel-stave, toroid-pore, and carpet 
theories (Prado Montes de Oca 2013; Wimley 2010; Yeaman and Yount 
2003). Besides the stable channel/pore complex formation suggested by 
carpet barrel or toroid theory, sinking-raft theory suggests that the transient 
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pore formation was due to mass imbalance caused by peptide preferential 
binding by self-association or self-assembly. This mass disproportion 
introduces a curvature strain along the outer membrane and forces the 
membrane to bend. Upon threshold concentration, the membrane breaks and 
the outer leaflet is linked to the inner leaflet for mass exchange. The 
membrane recovers again because the curvature stain dissipates as the result 
of the mass exchange. 
QCM-D is a recently developed technique to study bilayers. A QCM-D sensor 
consists of a thin quartz disc that can be excited to oscillation by AC 
A lipid bilayer is a good model for studying membranes. Expanding, 
contracting, and bending are the three main forms of deformation in the 
liposome bilayer (Disalvo and Simon 1995). Expanding and contracting are 
within-plane motions that are usually evaluated by the compressibility 
corresponding to the change in pressure vs. area per molecule in a membrane. 
Previous studies reported that membrane pressure prohibits pore formation 
(Farago and Santangelo 2005; Janmey and Kinnunen 2006; Karatekin et al. 
2003; Matsuzaki et al. 1998). Membrane bending is an out-of-plane movement 
that is closely related to the curvature strain, which in turn is regulated by the 
nature of the constituent lipids (Heerklotz 2008). The compressibility and 
curvature strain are characteristic properties that can be used to estimate the 
deformation ability of a lipid bilayer.  
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application because of its piezoelectric properties. When a thin and rigid layer 
is attached to the sensor, the oscillation frequency (f) would decrease, 
according to the Sauerbrey relationship, as follows: 
C=17.7ng Hz-1 cm-2 for a 5 MHz quartz crystal. 
N=1, 3, 5, 7 is the overtone number.  
The attached layer is “soft” and does not fully couple to the sensor in most 
cases. The mass was underestimated by the Sauerbrey relationship. This 
viscous film dampens the sensor’s oscillation. Energy dissipation (D) is 
introduced and defined as follows to estimate the viscosity:  
Where Elost is the energy lost (dissipated) during one oscillation cycle 
and Estored
Based on water coupling theory (Cho et al. 2007), the energy 
dissipation reflects the surface roughness.  
 is the total energy stored in the oscillator 
Ib-AMP4 from Impatients balsamina represents an interesting and powerful 
AMP with bactericidal properties against Gram-positive and Gram-negative 
bacteria and MDR pathogens. However, Ib-AMP4 antibacterial activity is 
largely affected by ion concentrations. We aimed to determine the 
antimicrobial mechanism and to clarify how divalent cations inhibit Ib-AMP4 
antimicrobial activity. 
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6.3 Result 
 6.3.1 Liposome leakage 
Our liposome preparation reached a homogeneous size of ~200 nm in 
diameter after extrusion. The free calcein was effectively removed, and only 
stable and non-leaky liposome fractions from PD-10 chromatography were 
used for the leakage assay. The leakage percentages in 1% Triton X-100 and 
HEPES buffers were 100% and 0%, respectively. 
Membrane disruption caused by Ib-AMP4 was studied using a calcein leakage 
kinetics assay. A series of peptide concentrations were added for the leakage 
assay. The P/L ratios used varied from 2.5/1 to 1/10. The release curve was 
characterized by a biphasic increase. A strong and instantaneous calcein 
release was observed within the first several minutes after peptide addition, 
followed by a slow and weak release that reached a plateau within 20 min. 
The leakage ratio was positively correlated with the peptide at concentrations 
below 50 μg/ml. A maximal leakage of ~65% was obtained by applying the 
peptide at 50 or 100 μg/ml, whereas a minimal leakage of ~3% was obtained 
by applying the peptide at 0.2 μg/ml. The addition of 50 mM calcium into the 
reaction buffer decreased leakage at all tested peptide concentrations. 
Leakage decreased by at least 40% after calcium addition at concentrations 
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higher than 0.5 μg/ml. Such concentrations were within the MICs range for 
bacteria. 
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Figure 18. Kinetics of DOPC liposome leakage by Ib-AMP4 in the calcium-free buffer. A 
concentration series of Ib-AMP4 ranging from 0.1 μg/ml to 200 μg/ml was tested on the 
DOPC liposome. The calcein leakage intensity was positively correlated with Ib-AMP4 at 
concentrations lower than 200 μg/ml.  
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Figure 19. Liposome leakage after treated with different concentrations of Ib-AMP4. 
Liposome prepared by DOPC and its binary mixture with DOPG or cholesterol were used. 
High, medium, and low concentrations (i.e., 100, 6.25, and 0.4 μg/ml, respectively) of 
Ib-AMP4 were tested. PC, DOPC liposome; PC/PG (4:6), liposome of the binary mixture 
of DOPC/DOPG with a molar ratio of 4:6; PC/Ch (7:3), liposome of the binary mixture of 
DOPC/cholesterol with a molar ratio 7:3. The leakage percentages at 25 min after peptide 
application are plotted in bars.  
The incorporation of DOPG or cholesterol into the DOPC membrane reduced 
the leakage percentage. Cholesterol and DOPG reduced the maximal leakage 
from ~80% to ~40% and ~30%, respectively. DOPC liposome and calcium 
addition inhibited the leakage of the mixed liposome, but the cholesterol-mixed 
liposome notably showed the lowest leakage after the addition of calcium.  
Calcium-free buffer 
Calcium-loaded buffer 
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6.3.2 Secondary structure of Ib-AMP4 
The DOPC-bound peptide indicated that β -sheet was the effective 
conformation by which Ib-AMP4 exerted membrane activity. An inactive 
peptide without disulfide bonds only had 6.6% β-sheet, whereas an active 
peptide with disulfide bonds had 25.3%. Disulfide bonds seemed to promote 
the refolding of an unstructured Ib-AMP4 peptide. Both Mg2+ and SDS reduced 
the β-sheet percentage, and such decrease corresponded to a suppression of 
the Ib-AMP4 antimicrobial activity.  
 
Figure 20. Secondary structures of Ib-AMP4 in different solutions. 
Table 9. Second structure of the Ib-Amp4 peptide. 
   
2D structure 
Solvents*  
 MgSO4 Pure water H2O DOPC 2 SDS   
α-Helix 0 0 0 0 16.2  
β-sheet 0 6.6 25.3 65.7 0 
Turn 48.4 45.7 27.9 0   0  
Random 51.6 47.7 46.9 34.3 83.8  
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*Ib-AMP4 peptide solved in “pure water” was inactive without disulfide bonds. The other 
samples were pre-treated with H2O2 to form disulfide bonds and were supplemented with 
different additives, such as DOPC, SDS, and MgSO4
6.3.3 DLS 
, for CD measurements.  
The prepared DOPC liposome showed an average size of ~165 nm in 
diameter. Size distribution results indicated that the whole liposome proportion 
was subject to a single peak, thereby suggesting that the liposome was 
prepared homogenously. 
Addition of the peptide into the DOPC liposome with a P/L ratio varying from 
1/6 to 2.5/1 failed to change the shape of the original size distribution curve. 
However, a minor mean size shift toward a larger diameter after peptide 
addition was observed. By contrast, the liposome melted down into tiny 
particles with a diameter of several nanometers in the presence of Triton 
X-100. 
 
 
Figure 21. Size distribution of liposome by DSL after the addition of Ib-AMP4 or Triton 
X-100. The mean sizes of the liposome were 162.8, 186.3, 198.0, and 216.4 nm after the 
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addition of 0, 5, 20, and 80 μg/ml Ib-AMP4, respectively. Triton X-100 transformed 
liposomes into small particles with diameters of several nanometers. 
6.3.4 TEM 
Most of the Escherichia coli cells were disrupted, and a portion of their 
cytoplasm was released to the external environment after Ib-AMP4 treatment. 
Several cells slightly shrunk as they lost their original shape, but still 
maintained a round stick shape. The cell wall remained intact because the 
cells were still surrounded by a clear envelope. The cells became leaky, but 
most of their cytoplasm remained inside. The leakage zone showed a 
cloud-like shape, thereby implying that leakage was restricted to a local region 
and only a few leaky pores were formed. 
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Figure 22. TEM image of Ib-AMP4 causing Escherichia coli cell leakage. Bacterial cells 
with condensed atom density appear black under TEM, whereas the bright areas 
represent either the extracellular buffer or leakage location where the cytoplasm was 
replaced by the water buffer. The arrows indicate leaky spots. 
6.3.5 GUV image 
The peptide started to diffuse from right to left in the sample chamber after 
peptide injection. The bilayer membrane rigidity increased with increasing 
peptide concentration. When the peptide reached the critical concentration, the 
GUVs suddenly exploded or started to shrink into a solid granule. This event 
occurred very rapidly, within 1 s on average. One of our photographs showed 
the step-by-step shrinkage of the GUVs. The image below indicates that a 
scar-like area was formed on the surface before the GUV started to shrink. The 
inner content continuously leaked out from the scar, and the GUV finally turned 
into a solid granule. 
 
Figure 23. Documentation of GUV breakage by Ib-AMP4 using time elapse photography. 
The black bar indicates the amplification scale per 100 μm. 
6.3.6 Isotherm for lipids 
The π-A isotherm for DOPC is shown in Figure 24. The compression profiles of 
the calcium-loaded and -free buffers were similar, indicating an expanded 
isotherm without apparent phase transition. The expansion of the isotherm can 
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be explained by the loose structure formed by unsaturated double bonds in the 
alkyl chains of DOPC. In contrast to LPS-Re, calcium addition induced the 
onset of pressure increase at a low molecular area. Pressure was maintained 
at a high level throughout the compression, but the gap was only 1 mN/m to 
3 mN/m, which was theoretically negligible. The condensation effect of divalent 
cations was also observed in other lipid monolayers (Ohki and Ohshima 1985; 
Ohshima and Ohki 1985; Yamaguchi et al. 1995).  
The incorporation of DOPG into DOPC failed to change the shape of the π-A 
isotherm. The produced isotherm seemed to overlay with that obtained from 
the calcium-loaded buffer. Cholesterol incorporation apparently changed the 
π-A isotherm shape and resulted in low pressure throughout the compression.  
 
Figure 24. Surface pressure area isotherms for DOPC and their binary mixtures. 
Monolayer isotherms of DOPC both in calcium-free and -loaded buffers were measured to 
evaluate the effect of calcium ions. DOPG and cholesterol were mixed with DOPC at a 1:1 
molar ratio and used for isotherm measurements.  
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6.3.7 DOPC QCM-D 
DOPC was applied onto the quartz, and a bilayer was absorbed onto the 
surface, corresponding to a frequency shift of ~26 Hz. The dissipation values 
below 0.5 suggested that the bilayer was well deposited with good rigidity. A 
serial solution of different peptide concentrations ranging from 5 μg/ml to 
400 μg/ml was applied to the DOPC bilayer. No apparent absorption was 
observed at concentrations lower than 400 μg/ml. At 400 μg/ml peptide 
concentration, a frequency shift of ~7 Hz was recorded. The washing step with 
the calcium buffer failed to change the binding/insertion. Consistent with the 
frequency, dissipation dramatically increased to 1.7 and higher after the 
application of the peptide at 400 μg/ml. 
 
Figure 25. QCM-D for DOPC after the application of Ib-AMP4 at different concentrations. 
Before each injection, the quartz was equilibrated for at least 10 min until the curves were 
steady. The arrows indicate the injection spots. A, Ib-AMP4 at 5 μg/ml; B, Ib-AMP4 at 
10 μg/ml; C, Ib-AMP4 at 20 μg/ml; D, Ib-AMP4 at 40 μg/ml; E, Ib-AMP4 at 80 μg/ml; F, 
Ib-AMP4 at 200 μg/ml; G, Ib-AMP4 at 400 μg/ml.  
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6.4 Discussion 
The naturally occurring amino acid sequence for Ib-AMP4 comprises 20 amino 
acids. Hydrophobic amino acids are present symmetrically at position 2, 9 and 
19. A multiple anti-parallel folding, which assembled the hydrophobic residues 
of Ib-AMP4, was the predicted reason for the membrane insertion. The 
disulfide restriction caused by connections at position 6, 20, 7 and 16, and the 
angle restriction by proline at position 9 indicated a quinary folding of each 
lamella comprising 4 to 5 amino acids. The basic charged groups of arginine 
only existed in pairs at the folding edge, whereas the hydrophobic residues 
were packed at the head. 
Ib-AMP4 is not a true amphipathic molecule before the conformational change. 
Ib-AMP4 failed to show any surfactant activity in pure water or aquatic buffers 
(data not shown). An inducible conformation change is required for Ib-AMP4 to 
exert amphipathic insertion. The CD spectrum results failed to show an 
apparent secondary structure for Ib-AMP4 in an aquatic buffer after forming 
disulfide bonds, but the merit of the disulfide bond became evident when 
improved efficiency was obtained in antimicrobial tests after the formation of 
disulfide bonds (Fan et al. 2013). The presence of the membrane-bound 
peptide with a ~70% β -sheet implied that membrane insertion was a 
conformation-dependent process (Nguyen et al. 2011). The disulfide 
bond-restrained conformation probably represents an intermediate for the 
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unstructured peptide to fold into a β -sheet. Cations inhibited Ib-AMP4 
antimicrobial efficiency by affecting the conformation transition stage because 
the β-sheet dissipated in the presence of magnesium cations or SDS was 
observed. 
AMPs use a unique mechanism to selectively target bacteria and are a 
promising solution to overcome drug resistance. However, AMP’s 
susceptibility to cations is the primary limitation for the wide application of 
AMPs. Cations, such as Ca2+ and Mg2+, are physiologically essential in all cell 
types. Their effect on the antimicrobial efficiency of AMPs killing bacteria is an 
interesting topic.  
As we discussed in the previous chapter, all substances entering or 
approaching the bacterial cell membrane pass through the cell wall. Unlike the 
cell membrane, which is only open for selected substances, the cell wall uses 
Ca2+ to reduce the permeability to Ib-AMP4. After crossing the cell wall, AMPs 
reach their real target, which is the cytoplasm membrane. Unlike the cell wall, 
the cell membrane is a sealed but selectively permeable bilayer. A lipid bilayer 
is a good model for studying the cell membrane. Spontaneous but slow 
leakage of calcein occurred in DOPC liposome, thereby indicating that the 
occasional opening of a membrane bilayer occurs naturally (Bordi et al. 2000). 
Membrane fluctuation transmits an occasional strain along the membrane 
where lipids move non-synchronously and dynamically changes the local 
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bilayer properties, such as thickness and tension; such properties are closely 
related to the insertion event (Santangelo and Farago 2007; Woodka et al. 
2012). Membrane fluctuation initiates the occasional membrane hydrophobic 
exposure for AMP insertion.  
Extended leakage can be caused by pore stabilization. Some studies suggest 
that surfactants stabilize pores by reducing the line tension, which helps reseal 
pores (Farago and Santangelo 2005; Janmey and Kinnunen 2006; Karatekin 
et al. 2003). Unlike the line tension, membrane surface tension drives the 
opening of the membrane (Farago and Santangelo 2005; Janmey and 
Kinnunen 2006; Karatekin et al. 2003; Matsuzaki et al. 1998). Logically, the 
opposing surface pressure prohibits the pore-formation on the membrane. 
Curvature is another important factor affecting membrane flexibility or 
fluctuation.  
From an energy perspective, previous experiments have proven that the 
insertion of amphipathic molecules into a lipid membrane is driven by enthalpy 
(i.e., energy minimization) (Yeaman and Yount 2003). The hydrophobic 
insertion is energetically favored and would occur spontaneously as the 
membrane expands and as the inserted peptides lose potential energy. 
However, the membrane cannot expand freely in a liposome where interior 
pressure increases after insertion. The potential energy produced by increased 
interior pressure is energetically unfavored. An alternative is to create a wrinkle 
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on the surface. DOPC/PC is a kind of lipid with a spontaneous negative 
curvature strain, but the outer leaflet bends positively. Therefore, curvature 
frustration occurs at the bilayer’s outer leaflet. S
Consistent with bactericidal kinetics (Fan et al. 2013), liposome leakage 
occurred for ~20 min and was dynamically constant for up to 24 h. Membrane 
corruption is the primary bactericidal effect of Ib-AMP4. This temporary 
leakage implied that the membrane was opened transiently, but no large mass 
from the membrane was removed. This condition was suggested by the DLS 
results, wherein neither apparent size change nor new particle generation was 
observed for the liposome after treatment with peptides at concentrations 
reaching 80 μg/ml. At these concentrations, ~70% leakage was observed in 
tress caused by the curvature 
failure, which stores elastic potential to an extent, favors insertion only if an 
opposite curvature strain is introduced (Marsh et al. 2006). Line tension, which 
is considered as the energy compensation for the hydrophobic exposure of a 
lipid membrane, drives the resealing of hydrophobic exposure. The value of 
line tension, such as in a pore of a given size, on a membrane depends on the 
length of the hydrophobic tail of the constituent lipids (Janmey and Kinnunen 
2006). The energy compensation for hydrophobic exposure is smaller for a 
molecule from a membrane with a smaller or shorter hydrophobic tail. This 
condition explains why Ib-AMP4, which has a small hydrophobic region, can 
drive a self-promoting insertion and can stabilize pores. 
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the leakage assay. We can distinguish the peptide membrane disruption 
mechanism from a carpet mechanism, which is a characteristic of small 
particle generation. Apparently, the peptide employed a non-membrane-lytic 
mechanism. Given that the peptide structure restrained by two disulfide bonds 
failed to reach a sufficient length to expand across the bilayer of ~5 nm, the 
barrel-stave pore mechanism was not applicable for Ib-AMP4. 
Rinsing with a subphase without a peptide failed to decrease the binding mass, 
which indicates a strong affinity between Ib-AMP4 and DOPC lipid in the 
settled buffer environment. Nevertheless, no apparent adsorption was 
observed at concentrations up to 200 μg/ml, but absorbed mass dramatically 
increased after Ib-AMP4 at 400 μg/ml was applied. This finding implies the 
existence of a threshold at which the peptide affinity towards the lipid bilayer 
dramatically increased. A reasonable explanation is that the binding/insertion 
target was not exposed until the threshold concentration was reached. A 
self-promoting event for peptide binding/insertion was assumed.  
The observed threshold by QCM-D was between 200 and 400 μg/ml. The 
threshold was much bigger than the sufficient concentration observed in the 
leakage assay using the same liposome species. This finding can be attributed 
to the changes in flexibility/fluctuation for the DOPC bilayer after 
immobilization (Karatekin et al. 2003; Matsuzaki et al. 1998). The immobilized 
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membrane with one side anchored to the quartz results in high stiffness and 
low flexibility (Disalvo and Simon 1995; Heerklotz 2008).  
The increase in the dissipation indicates the roughness of the DOPC bilayer 
surface after peptide insertion/binding. DOPC is prone to introducing a 
negative curvature strain onto the outer lipid leaflet (Heerklotz 2008), whereas 
Ib-AMP4 introduces a positive curvature strain because of its large hydrophilic 
headgroup and small hydrophobic tail. When Ib-AMP4 is aligned with the lipid, 
a fluctuant wrinkle instead of smooth adjacency occurs. The energy 
compensation for hydrophobic exposure of an Ib-AMP4 molecule with a small 
hydrophobic tail is smaller than that of a long lipid tail. Therefore, the induced 
weakness at the adjacent place increases the membrane’s propensity to open 
at local places where a peptide is already inserted. This finding explains the 
self-promoting insertion of Ib-AMP4 into the membrane and also 
The GUV image provides information on the pore formation. Before reaching 
the threshold concentration, the GUV membrane became increasingly rigid 
and then started to shrink when a pore was produced on the surface. However, 
unlike much smaller bacterial cells or small, unilamellar vesicle liposomes, 
GUVs are sensitive to osmotic pressure changes or curvature strain caused by 
peptide addition.  
clarifies why 
leakage is constrained at a local place, as observed by TEM.  
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How the membrane opens pores across the bilayer is still unknown, but pore 
opening is certainly dependent on peptide insertion. A high number of 
insertions cause increased leakage. These mechanisms outlined in the 
introduction suggest different pore forming patterns, but they all ignore the fact 
that the membrane would open spontaneously. Does the inner leaflet really 
need to adopt a similar mechanism to open in the same way as the outer 
leaflet? Determining what occurs in the inner layer is difficult because the area 
is hardly accessible for any monitor.  
The incorporation of a negatively charged DOPG into the membrane failed to 
increase leakage, but rather decreased the leakage caused by Ib-AMP4. This 
finding is consistent with the antimicrobial assay results wherein Escherichia 
coli exhibited stronger resistance to Ib-AMP4 than Staphylococcus aureus in 
salt-containing medium. However, their susceptibility to Ib-AMP4 was 
comparable in salt-free medium. If the net charge of the bacterial cells defines 
their susceptibility to AMPs, then the usefulness of all AMPs should be the 
same or similar. The preferred bacterial targets were distinguished for different 
AMPs, and the susceptibility to AMPs was unpredictable in terms of bacterial 
charge property. Therefore, charged lipids affect AMP distribution on the 
membrane surface, but this electrostatic effect is not as simple as we expected 
(Yamaguchi et al. 1995).  
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DOPG and DOPC share a very similar structure with only small differences 
existing at the headgroup, which introduced a negative charge to the DOPG. 
Thus, a comparison between DOPC and DOPC/DOPG mixture 
liposome/monolayer would contribute to the study on the effect of charge 
during membrane disruption. As expected, the DOPG incorporation failed to 
alter the isotherm curve shape, but slightly increased the surface pressure at 
the same molecular area. However, this increase is theoretically negligible. 
Compressibility is independent of charge during membrane expansion. 
Calcium addition produced nearly the same effects as DOPG incorporation 
into DOPC in both isotherm and calcein-leakage assays. This result could 
indicate that incorporating a negative charge to the membrane produces an 
effect similar to that obtained when cations are added into the environmental 
buffer. As of this writing, we lack sufficient case studies to reach such a 
conclusion, but determining the relationship linking buffer ions, membrane 
charges, and compressibility is interesting. 
The DOPG-mixed lipid bilayer can prevent deep insertion of the peptide by 
electrostatically absorbing the peptide at the lipid headgroup or using the same 
approach as that used for LPS to prohibit peptide binding by electrostatic 
repulsion. The compressibility has been modified by adding DOPG into DOPC, 
but only slightly. Unlike DOPG, cholesterol is a truly neutral compound, but 
with a strong negative curvature potential. Some reports state that negative 
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curvature-inducing lipids can prohibit pore formation (Matsuzaki et al. 1998). 
Other studies suggest that cholesterol can prevent membrane opening by 
increasing the line tension (Farago and Santangelo 2005). Thus, cholesterol 
plays a versatile role during membrane stabilization.  
The insertion finally eased after attenuating the bound Ib-AMP4 into the bulk 
context of the DOPC lipid-forming wrinkle on the surface as indicated by 
QCM-D. Deductively, this insertion decreased the compressibility of the bilayer 
as insertion occupied space and increased the membrane lateral pressure. 
The curvature failure was also fixed by introducing Ib-AMP4 of a spontaneous 
positive strain, which changed the bending modulus, thereby affecting the 
membrane flexibility/fluctuation (Zilman and Granek 1996). This condition 
explains why the liposome finally became resistant to the peptide, and why the 
calcein leakage of DOPC stopped increasing at concentrations above 50 
μg/ml. 
Ib-AMP4 can use a quartered mechanism to rupture the DOPC membrane. (i) 
The binding/insertion event is initiated by an occasional strain burst that opens 
gaps temporarily between adjacent molecules and exposes the hydrophobic 
area. The solution peptides therefore obtain access to the hydrophobic area of 
the outer leaflet for insertion by chance. Along with this insertion, a 
conformation change in the bound peptide significantly increases the 
interaction between lipids and bound peptides. (ii) This insertion increases the 
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tendency of opening the outer leaflet prone because the peptides introduce 
opposite spontaneous curvature strains to the bulk lipids on the membrane. 
Thus, the insertion spot would widen and more peptide insertions occur 
through a self-promoting mechanism. (iii) Thus, a transmembrane pore 
develops by a particular mechanism. The lateral pressure and line tension 
quickly reseal the pore and attenuate the bound peptides into the bulk lipid 
context. This triple cycle i.e., insertion-pore-resealing, occurs several times. (iv) 
Finally, the bilayer becomes resistant to the peptide after intensive insertion 
and reaches a stable stage where leakage was significantly decreased. 
Calcium ions can decrease LPS permeability to Ib-AMP4 at the cell envelope 
and also prevent the interaction between Ib-AMP4 and lipids by either 
electrical repulsion or interruption of peptide transformation.  
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Figure 26. Scheme for membrane interaction with Ib-AMP4. Ib-AMP4 needs to adopt a 
proper structure to intercalate into membrane. This insertion probably follows a 
mechanism similar to sinking-raft. The curvature strain, line tension and surface tension 
are involved during pore formation and resealing.  
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